Datasets:
ChatDOC
/
OCRFlux-pubtabnet-single

Dataset card Data Studio Files Community
image_name
stringlengths
68
68
type
stringclasses
2 values
gt_table
stringlengths
116
12.6k
c45122e8cce2c4f2b9195209cd589f573953f527ce96a31313375513fd67c2a1.png
simple
<table><tr><td>Group (n = 5)</td><td>Tumor volume(mm<sup>3</sup>)</td><td>Inhibitory Rate (%)</td><td>Tumor weight (g)</td><td>Inhibitory Rate (%)</td></tr><tr><td>control</td><td>2531.78 &#177; 153.25</td><td></td><td>1.194 &#177; 0.10</td><td></td></tr><tr><td>Tet (40 mg/kg)</td><td>1243.00 &#177; 55.19<sup>***</sup></td><td>50.90</td><td>0.641 &#177; 0.06<sup>***</sup></td><td>46.31</td></tr><tr><td>Tet(120 mg/kg)</td><td>493.06 &#177; 145.63<sup>***</sup></td><td>80.52</td><td>0.298 &#177; 0.09<sup>***</sup></td><td>75.04</td></tr></table>
de21fc2f4baca285a5b63fd8e109eb793b2b39ed9d4a807a8f7b583614004899.png
complex
<table><tr><td rowspan="2">Parameter</td><td rowspan="2">Base case (male, female)</td><td>Age 55 years</td><td>Age 60 years</td></tr><tr><td>Threshold</td><td>Threshold</td></tr><tr><td>First aseptic revision rate (early)</td><td>1.31%, 1.13%</td><td>Robust</td><td>Robust</td></tr><tr><td>First aseptic revision rate (late)</td><td>0.61%, 0.63%</td><td>Robust</td><td>Robust</td></tr><tr><td>First infection revision rate (early)</td><td>0.20%, 0.17%</td><td>Robust</td><td>Robust</td></tr><tr><td>First infection revision rate (late)</td><td>0.09%</td><td>Robust</td><td>Robust</td></tr><tr><td>End-stage osteoarthritis [1]</td><td>USD 12,815</td><td>Robust</td><td>Robust</td></tr><tr><td>Initial post-THA (365 days)</td><td>USD 38,965</td><td>USD 123,700 (female)USD 170,100 (male)</td><td>USD 78,800 (female)USD 116,900 (male)</td></tr><tr><td>Productivity</td><td>Varies by age and gender</td><td>26% of base (female)20% of base (male)</td><td>41% of base (female)28% of base (male)</td></tr></table>
0d5dbbf57c60ff479fb1dc1cca048a73f524b079a64cc00f9b2a5bd210dfebb0.png
complex
<table><tr><td>Characteristics</td><td>Mean (SD)</td><td>n (%)</td></tr><tr><td colspan="3">Gender</td></tr><tr><td>Male</td><td></td><td>162 (47.5)</td></tr><tr><td>Female</td><td></td><td>179 (52.5)</td></tr><tr><td colspan="3">Marital Status</td></tr><tr><td>Single</td><td></td><td>20 (5.9)</td></tr><tr><td>Married</td><td></td><td>257 (75.3)</td></tr><tr><td>Others</td><td></td><td>64 (18.8)</td></tr><tr><td colspan="3">Current Smoker</td></tr><tr><td>Yes</td><td></td><td>75 (22)</td></tr><tr><td>No</td><td></td><td>266 (78)</td></tr><tr><td colspan="3">Education</td></tr><tr><td>Less than secondary school</td><td></td><td>243 (71.3)</td></tr><tr><td>Diploma</td><td></td><td>45 (13.2)</td></tr><tr><td>Bachelor or higher</td><td></td><td>51 (15.5)</td></tr><tr><td colspan="3">Diabetes Treatment</td></tr><tr><td>Insulin</td><td></td><td>96 (28.2)</td></tr><tr><td>Oral tablet</td><td></td><td>165 (48.4)</td></tr><tr><td>Insulin + Oral tablet</td><td></td><td>78 (23.4)</td></tr><tr><td colspan="3">Blood Sugar Self-Monitoring</td></tr><tr><td>Yes</td><td></td><td>300 (88)</td></tr><tr><td>No</td><td></td><td>41 (12)</td></tr><tr><td>Age (yr)</td><td>55.2 (12.9)</td><td></td></tr><tr><td>Body Mass Index</td><td>29.7 (5.6)</td><td></td></tr><tr><td>Household members</td><td>4 (2.4)</td><td></td></tr><tr><td>Income (USD)</td><td>630 (425)</td><td></td></tr><tr><td>Duration of illness (years)</td><td>11.3 (9.2)</td><td></td></tr><tr><td>Glycated Hemoglobin</td><td>7.9 (1.9)</td><td></td></tr><tr><td>No. of Cigarettes/ day</td><td>4.4 (10.1)</td><td></td></tr></table>
ce5a487e1faf94a0498cdd4b3602a0369c4d73c7ada352958214bc768a537ea3.png
simple
<table><tr><td>Filtering Criteria</td><td>Number of SNPs Excluded</td><td>Number of SNPs Remaining</td></tr><tr><td>None</td><td>0</td><td>2,740,205</td></tr><tr><td>Multiple Variants hits</td><td>33,917</td><td>2,706,288</td></tr><tr><td>Heterozygous and Bias*</td><td>2,111,439</td><td>594,849</td></tr><tr><td>Flanking Sequence**</td><td>5,482</td><td>589,367</td></tr><tr><td>Candidate SNPs</td><td></td><td>589,367</td></tr></table>
2889fdaf2c346e44d545495d875e259a9faf162b6d7fde02adb4e4eb691d16b0.png
complex
<table><tr><td></td><td>Total cost</td><td>Medical cost</td><td>Drug cost</td></tr><tr><td colspan="4"><i>Crude cost change &#8211; binary indicator</i></td></tr><tr><td> Chronic users</td><td>20,161**(18,775&#8211;21,547)</td><td>10,925**(9637&#8211;12,213)</td><td>9236**(8841&#8211;9632)</td></tr><tr><td> Concomitant users</td><td>16,666**(15,893&#8211;17,439)</td><td>11673**(10,954&#8211;12,392)</td><td>4993**(4772&#8211;5214)</td></tr><tr><td> Opioid disorder</td><td>15,026**(13,306&#8211;16,746)</td><td>11,974**(10,377&#8211;13,571)</td><td>3051**(2559&#8211;3544)</td></tr><tr><td colspan="4"><i>Adjusted cost change (with covariates and weighting) &#8211; binary indicator</i></td></tr><tr><td> Chronic users</td><td>6216**(5678&#8211;6754)</td><td>281(&#8722;123 to 795)</td><td>5935**(5808&#8211;6063)</td></tr><tr><td> Concomitant users</td><td>637*(134&#8211;1140)</td><td>-1036**(&#8722;1518 to &#8722;553)</td><td>1673**(1546&#8211;1799)</td></tr><tr><td> Opioid disorder</td><td>1558**(1039&#8211;2076)</td><td>671**(161&#8211;1181)</td><td>887**(809&#8211;964)</td></tr><tr><td colspan="4"><i>Crude cost change (one level increase in severity) &#8211; severity level (0&#8211;3)</i></td></tr><tr><td> Severity of chronic users</td><td>8845**(8205&#8211;9486)</td><td>4523**(3928&#8211;5119)</td><td>4322**(4139&#8211;4505)</td></tr><tr><td> Severity of concomitant users</td><td>7343**(6987&#8211;7700)</td><td>4959**(4628&#8211;5291)</td><td>2384**(2282&#8211;2486)</td></tr><tr><td> Severity of opioid disorder</td><td>6206**(5390&#8211;7022)</td><td>4880**(4123&#8211;5637)</td><td>1326**(1093&#8211;1560)</td></tr><tr><td colspan="4"><i>Adjusted cost change (with covariates: one level increase in severity) &#8211; severity level (0&#8211;3)</i></td></tr><tr><td> Severity of chronic users</td><td>3337**(2695&#8211;3978)</td><td>263(&#8722;344 to 869)</td><td>3074**(2887&#8211;3261)</td></tr><tr><td> Severity of concomitant users</td><td>1209**(840&#8211;1579)</td><td>315(&#8722;34 to 664)</td><td>895**(787&#8211;1002)</td></tr><tr><td> Severity of opioid disorder</td><td>1136*(206&#8211;2067)</td><td>809(&#8722;70 to 1688)</td><td>328*(56&#8211;599)</td></tr></table>
c5adf3bcf69d65954db1cbd728582c9325992429f537879df0918c8f5fa1ba9a.png
complex
<table><tr><td></td><td colspan="2">Patients with dementia N = 1059</td><td colspan="2">Comparison patients N = 5543</td></tr><tr><td>Non-Osteoporosis group</td><td>N</td><td>%</td><td>N.</td><td>%</td></tr><tr><td>Total</td><td></td><td></td><td></td><td></td></tr><tr><td>Non-osteoporosis</td><td>177</td><td>16.71</td><td>768</td><td>13.86</td></tr><tr><td>Crude HR (95% CI)</td><td colspan="2">1.36 (1.15- 1.60)*</td><td colspan="2">1.00</td></tr><tr><td>Adjusted HR (95% CI)</td><td colspan="2">1.35 (1.11- 1.64)*</td><td colspan="2">1.00</td></tr><tr><td>Hip fracture</td><td></td><td></td><td></td><td></td></tr><tr><td>Non-osteoporosis</td><td>84</td><td>7.93</td><td>242</td><td>4.37</td></tr><tr><td>Crude HR (95% CI)</td><td colspan="2">2.04 (1.59- 2.62)*</td><td colspan="2">1.00</td></tr><tr><td>Adjusted HR (95% CI)</td><td colspan="2">1.84 (1.37- 2.46)*</td><td colspan="2">1.00</td></tr><tr><td>Wrist fracture</td><td></td><td></td><td></td><td></td></tr><tr><td>Non-osteoporosis</td><td>34</td><td>3.21</td><td>142</td><td>2.56</td></tr><tr><td>Crude HR (95% CI)</td><td colspan="2">1.32 (0.87- 1.99)</td><td colspan="2">1.00</td></tr><tr><td>Adjusted HR (95% CI)</td><td colspan="2">1.48 (0.93- 2.43)</td><td colspan="2">1.00</td></tr><tr><td>Vertebral fracture</td><td></td><td></td><td></td><td></td></tr><tr><td>Non-osteoporosis</td><td>48</td><td>4.53</td><td>335</td><td>6.04</td></tr><tr><td>Crude HR (95% CI)</td><td colspan="2">0.86 (0.64- 1.17)</td><td colspan="2">1.00</td></tr><tr><td>Adjusted HR (95% CI)</td><td colspan="2">0.88 (0.62- 1.25)</td><td colspan="2">1.00</td></tr></table>
0cb2651a358636b72adb787701a911dc31c6f53fd0a80e7c585d99c71c4be044.png
complex
<table><tr><td>Congenital Malformation</td><td colspan="5">Count of Exposures</td></tr><tr><td></td><td>Number of dyads</td><td colspan="2">Fathers (max/individual = 3)</td><td colspan="2">Mothers (max/individual = 2)</td></tr><tr><td></td><td></td><td>Cases</td><td>Controls</td><td>Cases</td><td>Controls</td></tr><tr><td>Multifactorial conditions with morphologic anomalies (excluding hip)</td><td>97</td><td>42</td><td>27</td><td>23</td><td>20</td></tr><tr><td>Hip dysplasia and dislocation</td><td>20</td><td>16</td><td>4</td><td>13</td><td>2</td></tr></table>
d7da4b6798480578b76f467e6850b59e9b9edb9879fd62c5d1975fd9c0ce81e5.png
simple
<table><tr><td>Cancer type</td><td>Mechanism</td><td>Agent</td><td>Phase</td></tr><tr><td>Melanoma</td><td>Anti-CTLA-4</td><td>Ipilimumab</td><td>FDA approved</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Nivolumab</td><td>Phase III</td></tr><tr><td>Melanoma</td><td>Anti-PD-1</td><td>Pembrolizumab</td><td>FDA approved</td></tr><tr><td>Melanoma</td><td>Adoptive cell therapy</td><td> </td><td>Phases I-II</td></tr><tr><td>Melanoma</td><td>Peptide Vaccine</td><td>Melan-A peptides</td><td>Phases I-II</td></tr><tr><td>Melanoma</td><td>Autologous DC vaccine</td><td> </td><td>Phases I-II</td></tr><tr><td>Melanoma</td><td>Whole tumor cell vaccine</td><td> </td><td>Phases I-II</td></tr><tr><td>NSCLC</td><td>Peptide vaccine</td><td>EGFR peptide</td><td>Phase III</td></tr><tr><td>NSCLC</td><td>Anti-CTLA-4</td><td>Ipilimumab</td><td>Phase III</td></tr><tr><td>NSCLC</td><td>Anti-PD-1</td><td>Nivolumab</td><td>Phase II</td></tr></table>
25057fe7d785b93fcdba090dab02521fb9b5040a11fca9ba875e01cc21f18f55.png
simple
<table><tr><td>Item</td><td>Never</td><td>Seldom (&lt; 1/month)</td><td>Occasionally (1 to 3 times/month)</td><td>Often (1 to 2 times/week)</td><td>Frequently (&#8805;3 times/week)</td></tr><tr><td></td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td></tr><tr><td>Applied to patient care</td><td>0 (0)</td><td>3 (14)</td><td>7 (33)</td><td>8 (38)</td><td>3 (14)</td></tr><tr><td>Reinforced by senior residents and faculty</td><td>0 (0)</td><td>4 (19)</td><td>12 (57)</td><td>5 (24)</td><td>0 (0)</td></tr></table>
48ee398c87dd426524e19b1057848187b1288f4f147b30d140c621880c4929b5.png
simple
<table><tr><td>Drug</td><td>Target</td><td>Rat study standard findings</td><td>Human clinical findings</td><td>MMtox prediction</td></tr><tr><td>Captopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (&#8727;)</td></tr><tr><td>Lisinopril</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes (&#8727;)</td></tr><tr><td>Cyclosporin A</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Doxorubicin</td><td>Kidney</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Phenytoin</td><td>Kidney</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Captopril</td><td>Liver</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Cyclosporin A</td><td>Liver</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Doxorubicin</td><td>Liver</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Lisinopril</td><td>Liver</td><td>No</td><td>No</td><td>No</td></tr><tr><td>Phenytoin</td><td>Liver</td><td>No</td><td>Yes</td><td>Yes</td></tr><tr><td>Cyclosporin A</td><td>Anemia</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Doxorubicin</td><td>Anemia</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Captopril</td><td>Bone marrow</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Lisinopril</td><td>Platelet</td><td>Yes</td><td>Yes</td><td>Yes</td></tr></table>
bfbdbe365487b672e94af3baa627f765decfa2814e6473b20e23653a9a0fe661.png
simple
<table><tr><td>Test Material/Chemical</td><td>Experimental Model</td><td>Findings</td><td>Reference</td></tr><tr><td>Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)</td><td>Mouse 3T3-L1 preadipocytes</td><td>&#8595; accumulation of lipid droplets in adipocytes;&#8595; protein levels of key adipogenesis transcription factors: PPAR&#947;, CCAAT/enhancer binding protein (C/EBP) &#946;, and C/EBP&#948; &amp; fatty acid synthase;&#8593; NAD<sup>+</sup>-dependent histone deacetylases (SIRT1) and activated AMP-activated protein kinase (AMPK) signaling in differentiated 3T3-L1 adipocytes.</td><td>[63]</td></tr><tr><td>Brown seaweed extract (10% fucoxanthin)</td><td>Human adipose-derived stem cells</td><td>&#8595; ROS;Silencing of palmitic acid-induced long non-coding RNAs (lncRNAs) resulted in the decrease in lipid droplet accumulation</td><td>[57]</td></tr><tr><td>Fucoxanthin-rich wakame (<i>Undaria</i>) lipids (WL)</td><td>Mouse (Type 2 diabetes/obese model)</td><td>&#8595; body weight and white adipose weight;&#8595; plasma levels of leptin;&#8593; mRNA expression of &#946;3-adrenergic receptor (Adrb3) in WAT and glucose transporter 4 (GLUT4) mRNA in skeletal muscle tissues</td><td>[45]</td></tr><tr><td>Fucoxanthin &amp; Fucoxanthinol</td><td>Mouse (Type 2 diabetes/obese model)</td><td>Improved glucose tolerance;&#8595; TNF-&#947; and MCP-1 expression in WAT</td><td>[48]</td></tr><tr><td>Capsule containing omega-3 PUFA-rich scallop phospholipids (PL) with incorporation of <i>Undaria</i> lipids (UL) containing fucoxanthin</td><td>Mouse</td><td>&#8595; body weight and WAT weight;&#8593; UCP1 and mRNA expression of UCP1 in epididymal fat</td><td>[53]</td></tr><tr><td>Fucoxanthin (pure chemical)</td><td>Mouse</td><td>&#8595; IL-1&#946;, TNF-&#945;, iNOS, and COX-2, and suppressed maleic dialdehyde (MDA) and infiltration of polymorphonuclear cells (PMN)</td><td>[47]</td></tr><tr><td><i>Petalonia binghamiae</i> extract containing fucoxanthin</td><td>Mouse</td><td>&#8595; body weight gain, adipose tissue weight and cell size, fatty droplet accumulation in the liver, and serum triacylglycerol level;&#8595; phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) in epididymal adipose tissue</td><td>[58]</td></tr><tr><td>Fucoxanthin (isolated from dried <i>Undaria pinnatifida</i>)</td><td>Mouse</td><td>&#8595; plasma triacylglycerols with a concomitant;&#8593; fecal lipids;&#8595; hepatic lipid contents;&#8595; activity of the hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, malic enzyme, fatty acid synthase and phosphatidate phosphohydrolase;&#8593; activity of &#946;-oxidation;&#8593; plasma HDL-cholesterol concentrations;&#8595; glucose and HbA1c</td><td>[51]</td></tr><tr><td>Fucoxanthin oil (1% fucoxanthin) + conjugated linolenic acid (CLA)</td><td>Rat</td><td>&#8595; triacylglycerol and leptin levels;&#8593; mRNA expression of adiponectin, adipose triacylglycerol lipase and carnitine palmitoyltransferase 1A</td><td>[50]</td></tr><tr><td>Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil)</td><td>Human subjects</td><td>&#8595; body weight, waist circumference, body and liver fat content, liver enzymes (NAFLD group only), serum triacylglycerols and C-reactive protein</td><td>[62]</td></tr></table>
a83e195256a896610895f7e6174c004113236875c1245549e5684f63170d3ad6.png
simple
<table><tr><td>Variable</td><td>HR* (95% CI)</td><td>p value </td></tr><tr><td>Age </td><td>1.04 (1.01&#8211;1.07)</td><td>0.014</td></tr><tr><td>Loss of Hemoglobin</td><td>1.23 (1.03&#8211;1.47)</td><td>0.023</td></tr><tr><td>Biopsy proven rejection</td><td>2.4 (1.41&#8211;4.0)</td><td>0.001</td></tr></table>
1fcba135271590b192a139f71668f35cc0d54a02e0170551e546335dde6712d6.png
simple
<table><tr><td>Scale</td><td>Measures</td></tr><tr><td>Physical Component</td><td></td></tr><tr><td> Physical functioning (PF)</td><td>Limitations in physical activities due to health problems</td></tr><tr><td> Role-physical (RP)</td><td>Limitations in usual daily activities due to health problems</td></tr><tr><td> Bodily pain (BP)</td><td>Pain experienced due to health problems</td></tr><tr><td> General health (GH)</td><td>General health perceptions</td></tr><tr><td> Vitality (VT)</td><td>Self-perceived energy and fatigue</td></tr><tr><td>Mental Component</td><td></td></tr><tr><td> Social functioning (SF)</td><td>Limitations in social activities due to physical or emotional problems</td></tr><tr><td> Role-emotional (RE)</td><td>Limitations in usual daily activities due to emotional problems</td></tr><tr><td> Mental health (MH)</td><td>Perceived well-being and the presence of any psychological distress</td></tr></table>
2b31d19b9dbfc2b5b6a8f7cb34b81bcee9d6b9943eab1d0e6e5810f4e4d9fdfd.png
complex
<table><tr><td rowspan="2">Risk factors</td><td colspan="3">Univariate analysis</td><td colspan="3">Multivariate analysis</td></tr><tr><td>HR</td><td>p-value</td><td>95% CI</td><td>HR</td><td>p-value</td><td>95% CI</td></tr><tr><td>Lucat1 expression</td><td>1.155</td><td>0.000<sup>**</sup></td><td>1.082-1.233</td><td>1.124</td><td>0.002<sup>**</sup></td><td>1.043-1.211</td></tr><tr><td>Age</td><td>1.695</td><td>0.002<sup>**</sup></td><td>1.220-2.354</td><td>1.488</td><td>0.018<sup>*</sup></td><td>1.070-2.070</td></tr><tr><td>Grade</td><td>2.421</td><td>0.000<sup>**</sup></td><td>1.692-3.463</td><td>1.489</td><td>0.040<sup>*</sup></td><td>1.017-2.179</td></tr><tr><td>Stage</td><td>4.308</td><td>0.000<sup>**</sup></td><td>3.046-6.095</td><td>2.466</td><td>0.000<sup>**</sup></td><td>1.624-3.744</td></tr><tr><td>M</td><td>4.765</td><td>0.000<sup>**</sup></td><td>3.424-6.632</td><td>2.299</td><td>0.000<sup>**</sup></td><td>1.564-3.380</td></tr><tr><td>T</td><td>3.597</td><td>0.000<sup>**</sup></td><td>2.588-5.001</td><td></td><td></td><td></td></tr><tr><td>N</td><td>2.821</td><td>0.002<sup>**</sup></td><td>1.484-5.365</td><td></td><td></td><td></td></tr><tr><td>Recurrence</td><td>2.407</td><td>0.000<sup>**</sup></td><td>1.745-3.319</td><td></td><td></td><td></td></tr><tr><td>Gender</td><td>1.022</td><td>0.896</td><td>0.737-1.418</td><td></td><td></td><td></td></tr></table>
2da33c0d2fd2ee2094ea12853f89f2a96aaed83978c550d4685036a9bf45f3a8.png
simple
<table><tr><td>Parameters</td><td>Proposed Sensor </td><td>XTE-190</td></tr><tr><td>Operational mode</td><td>Absolute</td><td>Absolute</td></tr><tr><td>Pressure range</td><td>2 MPa</td><td>1.7 MPa</td></tr><tr><td>Compensated temperature range</td><td>+20&#8211;220 &#176;C</td><td>+25&#8211;232 &#176;C</td></tr><tr><td>Sensitivity (10 V power supply)</td><td>210 mV/100 kPa</td><td>8 mV/100 kPa</td></tr><tr><td>Thermal zero shift Thermal sensitivity shift</td><td>&#177;1.2%FS/100F &#177;1.2%/100F</td><td>&#177;1%FS/100F &#177;1%/100F</td></tr><tr><td>Total accuracy in compensation temperature range</td><td>&#177;2%FS</td><td>&#177;1.5%FS</td></tr></table>
52fc3b955005ff7269d2d43dd37f0cb10d7f3c3c8496acfe11a1d5ce0dd0390a.png
simple
<table><tr><td>Syntax Score Category</td><td>Low(&lt;22)(n=83)</td><td>Intermediate(23-32)(n=36)</td><td>High(&gt;32) p(n=21)</td><td> p </td></tr><tr><td>Age (years), <i>mean</i><i>Minimum-Maximum</i><i>95% CI</i></td><td>65.843-97(63.6-67.9)</td><td>70.346-87(66.8-73.8)</td><td>66.9 47-83(62.8-71.1)</td><td>0.074</td></tr><tr><td>Sex (male)</td><td>77 (92.77%)</td><td>32 (88.89%)</td><td>21 (100%) </td><td>0.291</td></tr><tr><td>Smoker</td><td>32 (38.55%)</td><td>10 (27.77%)</td><td>8 (38.1%)</td><td>0.514</td></tr><tr><td>Hyperlipidemia</td><td>47 (56.62%)</td><td>28 (77.78%)</td><td>8 (38.1%) </td><td>0.010</td></tr><tr><td>Hypertension</td><td>50 (60.24%)</td><td>30 (83.33%)</td><td>12 (57.14%)</td><td>0.034</td></tr><tr><td>Diabetes mellitus</td><td>27 (32.53%)</td><td>13 (36.11%)</td><td>6 (28.57%)</td><td>0.839</td></tr><tr><td>Family History</td><td>22 (26.5%)</td><td>7 (19.44%)</td><td>2 (9.52%) </td><td>0.222</td></tr><tr><td>Overweight</td><td>9 (10.84%)</td><td>1 (2.77%)</td><td>2 (9.52%)</td><td>0.348</td></tr><tr><td>CAD</td><td>21 (25.3%)</td><td>7 (19.44%)</td><td>4 (19.04%)</td><td>0.708</td></tr></table>
b56014be0943a2b3573052caacdb23b880fb89f256771c44bc4118af95184080.png
complex
<table><tr><td>Type of cells</td><td colspan="7">Bladder cancer cell line</td></tr><tr><td></td><td>T24</td><td>RT4</td><td>5637</td><td>SW780</td><td>UMUC3</td><td>HT1376</td><td>TSSCUP</td></tr><tr><td>Unsorted</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>CD44<sup>high</sup></td><td>7/10</td><td>5/10</td><td>3/10</td><td>3/10</td><td>5/10</td><td>2/10</td><td>5/10</td></tr><tr><td>CD44<sup>low</sup></td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr></table>
854c5449537f03bd83bc493d68728c8ca6c566118946af74f8af3b2e15f1377e.png
complex
<table><tr><td colspan="3">Mechanical incremental steps compression</td></tr><tr><td>Compression factor</td><td>Intraparticle porosity</td><td>Voidage space</td></tr><tr><td>(&#955;)</td><td>(<i>&#949;</i><sub><i>p</i></sub>)</td><td>(<i>&#949;</i>)</td></tr><tr><td>0.00</td><td>0.63</td><td>0.41</td></tr><tr><td>0.02</td><td>0.60</td><td>0.39</td></tr><tr><td>0.05</td><td>0.63</td><td>0.36</td></tr><tr><td>0.10</td><td>0.62</td><td>0.33</td></tr><tr><td>0.15</td><td>0.60</td><td>0.31</td></tr></table>
aa6167aba51afa0f768c57d9b5131559bc245d9e68c39046fb5df9d67feb38f0.png
simple
<table><tr><td>Group</td><td>Treatment</td><td>Sham</td></tr><tr><td>Men/women (number of patients)</td><td>3/17</td><td>4/16</td></tr><tr><td>Age (years)</td><td>43.5 &#177; 11.07</td><td>43.55 &#177; 7.82</td></tr><tr><td>Headache history (years)</td><td>15.25 &#177; 8.37</td><td>18.75 &#177; 9.98</td></tr><tr><td>Baseline VAS</td><td>7.75 &#177; 0.96</td><td>7.45 &#177; 0.88</td></tr><tr><td>Baseline headache duration (days/month)</td><td>21.05 &#177; 3.36</td><td>19.65 &#177; 3.66</td></tr><tr><td>Baseline MIDAS score</td><td>63.05 &#177; 19.89</td><td>63.60 &#177; 16.59</td></tr></table>
b3186c48379ed32a672f1943b75e779ae27c9fc4ea664b52c05712d468524edd.png
complex
<table><tr><td></td><td colspan="8">Furosemide</td><td colspan="8">Placebo</td></tr><tr><td></td><td colspan="4">PEFR</td><td colspan="4">FEV1.0</td><td colspan="4">PEFR</td><td colspan="4">FEV 1.0</td></tr><tr><td>Study (year)</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Post-treatment airflow</td><td>SD</td></tr><tr><td>Alshehri and colleagues, 2005 [5]</td><td>59.0</td><td>22.0</td><td>84.9</td><td>14.0</td><td>58.5</td><td>14.5</td><td>80.2</td><td>13.9</td><td>57.2</td><td>25.4</td><td>80.7</td><td>17.4</td><td>56.7</td><td>17.3</td><td>77.8</td><td>19.1</td></tr><tr><td>Nuhog&#774;lu and colleagues, 2006 [3]</td><td>178</td><td>65.9</td><td>222</td><td>66.1</td><td>N/A</td><td>N/A</td><td>183</td><td>51.7</td><td>218</td><td>60.3</td><td>N/A</td><td>N/A</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Baseline airflow</td><td>SD</td><td>Net airflow improvement above baseline</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Net airflow improvement above baseline</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Net airflow improvement above baseline</td><td>SD</td><td>Baseline airflow</td><td>SD</td><td>Net airflow improvement above baseline</td><td>SD</td></tr><tr><td>Gonza&#769;lez-Sa&#769;nchez and colleagues, 2002 [4]</td><td>N/A</td><td>N/A</td><td>0.820</td><td>0.460</td><td>0.910</td><td>0.067</td><td>N/A</td><td>N/A</td><td>0.850</td><td>0.340</td><td>0.980</td><td>0.078</td><td></td><td></td><td></td><td></td></tr><tr><td>Nannini and colleagues, 1992 [1]</td><td>147</td><td>68.0</td><td>269</td><td>89.7</td><td>N/A</td><td>N/A</td><td>234</td><td>82.0</td><td>316</td><td>56.2</td><td>N/A</td><td>N/A</td><td></td><td></td><td></td><td></td></tr><tr><td>Ono and colleagues, 1997 [6]</td><td>171</td><td>20.0</td><td>205</td><td>45.1</td><td>1.18</td><td>0.13</td><td></td><td>178</td><td>25.0</td><td>198</td><td>21.3</td><td>1.32</td><td>0.74</td><td>N/A</td><td></td><td></td></tr><tr><td>Pendino and colleagues, 1998 [2]</td><td>200</td><td>71.0</td><td>426</td><td>98.0</td><td>N/A</td><td>N/A</td><td>209</td><td>68.0</td><td>337</td><td>73.2</td><td>N/A</td><td>N/A</td><td></td><td></td><td></td><td></td></tr></table>
a89fb4e93a51ddd895e9a8b2a9f341cfbb7c4bc12fed90b7065fb8c78883dba5.png
complex
<table><tr><td rowspan="2">Determinants</td><td rowspan="2">Food-hygiene practice</td><td colspan="3">Diarrhea</td></tr><tr><td>%</td><td>Unadjusted OR (95% CI)</td><td>Adjusted<sup>a </sup>OR (95% CI)</td></tr><tr><td>All children</td><td>Poor</td><td>11</td><td>1.15 (0.51&#8211;2.60)</td><td>1.33 (0.57&#8211;3.14)</td></tr><tr><td> </td><td>Better</td><td>9</td><td>1.00</td><td>1.00</td></tr><tr><td> </td><td><i>p-</i>value</td><td> </td><td>0.73</td><td>0.51</td></tr><tr><td colspan="2">Stratified by age group</td><td> </td><td> </td><td> </td></tr><tr><td>&#8804; 2 y (n = 93)</td><td>Poor</td><td>23</td><td>2.63 (0.78&#8211;8.89)</td><td>4.55 (1.08&#8211;19.10)<sup>*</sup></td></tr><tr><td> </td><td>Better</td><td>10</td><td>1.00</td><td>1.00</td></tr><tr><td> </td><td><i>p-</i>value</td><td> </td><td>0.12</td><td>0.04<sup>*</sup></td></tr><tr><td>&gt; 2 y (n = 181)</td><td>Poor</td><td>5</td><td>0.55 (0.17&#8211;1.78)</td><td>0.62 (0.18&#8211;2.14)</td></tr><tr><td> </td><td>Better</td><td>9</td><td>1.00</td><td>1.00</td></tr><tr><td> </td><td><i>p-</i>value</td><td> </td><td>0.32</td><td>0.38</td></tr></table>
2f04d54bf72318b01443391a31610b1354f3fda883ae295771328c1da536d8f9.png
simple
<table><tr><td>MODEL</td><td>&#967;<sup>2</sup>/df</td><td>GFI</td><td>AGFI</td><td>NFI</td><td>IFI</td><td>CFI</td><td>RMR</td><td>RMSEA</td></tr><tr><td>Experience value</td><td>2.0-5.0</td><td>&gt;0.90</td><td>&gt;0.90</td><td>&gt;0.90</td><td>&gt;0.90</td><td>&gt;0.90</td><td>&lt;0.10</td><td>&lt;0.08</td></tr><tr><td>Model R<sub>T</sub>(Total sample)</td><td>4.557</td><td>0.908</td><td>0.897</td><td>0.904</td><td>0.912</td><td>0.911</td><td>0.053</td><td>0.077</td></tr><tr><td>Model R<sub>W</sub>(Wuhan)</td><td>4.693</td><td>0.904</td><td>0.893</td><td>0.900</td><td>0.908</td><td>0.909</td><td>0.058</td><td>0.077</td></tr><tr><td>Model R<sub>S</sub>(Shiyan)</td><td>3.370</td><td>0.911</td><td>0.902</td><td>0.906</td><td>0.912</td><td>0.912</td><td>0.050</td><td>0.076</td></tr><tr><td>Model R<sub>J</sub>(Jingmen)</td><td>4.187</td><td>0.905</td><td>0.893</td><td>0.903</td><td>0.910</td><td>0.911</td><td>0.054</td><td>0.077</td></tr></table>
43af0dc0dbd541fddc8df4911fc337fa2dbf38be8e9f3e2efd1a2ade1c2bd00a.png
complex
<table><tr><td></td><td></td><td colspan="2">Specific Production (&#956;mol/min/mg)</td></tr><tr><td>Substrate</td><td>Product</td><td>Monohydroxy Fatty Acid</td><td>Dihydroxy Fatty Acid</td></tr><tr><td>Palmitoleic acid (16:1<sup>&#916;9</sup><i><sup>Z</sup></i>)</td><td>8-HHME</td><td>9.6 &#177; 0.2</td><td>NA</td></tr><tr><td>Oleic acid (18:1<sup>&#916;9</sup><i><sup>Z</sup></i>)</td><td>8-HOME</td><td>9.0 &#177; 0.1</td><td>NA</td></tr><tr><td>Linoleic acid (18:2<sup>&#916;9</sup><i><sup>Z</sup></i><sup>,12</sup><i><sup>Z</sup></i>)</td><td>8-HODE, 8,11-DiHODE</td><td>10.8 &#177; 0.1</td><td>1.4 &#177; 0.0</td></tr><tr><td>Conjugated linoleic acid (18:2<sup>&#916;9</sup><i><sup>E</sup></i><sup>,12</sup><i><sup>E</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>&#945;-Linolenic acid (18:3<sup>&#916;9</sup><i><sup>Z</sup></i><sup>,12</sup><i><sup>Z</sup></i><sup>,15</sup><i><sup>Z</sup></i>)</td><td>8-HOTrE, 8,11-DiHOTrE</td><td>14.9 &#177; 0.0</td><td>1.1 &#177; 0.0</td></tr><tr><td>&#947;-Linolenic acid (18:3<sup>&#916;6</sup><i><sup>Z</sup></i><sup>,9</sup><i><sup>Z</sup></i><sup>,12</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Eicosadienoic acid (20:2<sup>&#916;11</sup><i><sup>Z</sup></i><sup>,14</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Dihomo-&#947;-linolenic acid (20:3<sup>&#916;8</sup><i><sup>Z</sup></i><sup>,11</sup><i><sup>Z</sup></i><sup>,14</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Arachidonic acid (20:4<sup>&#916;5</sup><i><sup>Z</sup></i><sup>,8</sup><i><sup>Z</sup></i><sup>,11</sup><i><sup>Z</sup></i><sup>,14</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Docosapentaenoic acid (22:5<sup>&#916;</sup><i><sup>7Z</sup></i><sup>,10</sup><i><sup>Z</sup></i><sup>,13</sup><i><sup>Z</sup></i><sup>,16</sup><i><sup>Z</sup></i><sup>,119</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td>Docosahexaenoic acid (22:6<sup>&#916;4</sup><i><sup>Z</sup></i><sup>,7</sup><i><sup>Z</sup></i><sup>,10</sup><i><sup>Z</sup></i><sup>,13</sup><i><sup>Z</sup></i><sup>,16</sup><i><sup>Z</sup></i><sup>,19</sup><i><sup>Z</sup></i>)</td><td>NA</td><td>NA</td><td>NA</td></tr></table>
6ec913de21ab3dd18d891840b584b0469d1cf68de560f208865c987584c3d8a9.png
complex
<table><tr><td colspan="2">Up-Regulated Genes</td><td colspan="2">Down-Regulated Genes</td></tr><tr><td>Gene Symbol</td><td>Gene Name</td><td>Gene Symbol</td><td>Gene Name</td></tr><tr><td><i>APOLD1</i></td><td>Apolipoprotein L domain containing 1</td><td><i>AMD1</i></td><td>S-adenosylmethionine decarboxylase 1</td></tr><tr><td><i>Atrogin-1</i></td><td>F-box protein 32/Atrogin-1</td><td><i>AMIGO2</i></td><td>Adhesion molecule with Ig-like domain 2</td></tr><tr><td><i>BCL6</i></td><td>B-cell CLL/lymphoma 6</td><td><i>ATP13A3</i></td><td>ATPase type 13A3</td></tr><tr><td><i>BTG1</i></td><td>B-cell translocation gene 1</td><td><i>BAG2</i></td><td>BCL2-associated athanogene 2</td></tr><tr><td><i>C1orf183</i></td><td>Chromosome 1 open reading frame 183</td><td><i>BDNF</i></td><td>Brain-derived neurotrophic factor</td></tr><tr><td><i>C1orf63</i></td><td>Chromosome 1 open reading frame 63</td><td><i>BIRC3/cIAP2</i></td><td>Baculoviral IAP repeat-containing 3</td></tr><tr><td><i>CCNG2</i></td><td>Cyclin G2</td><td><i>CCL2</i></td><td>Chemokine (C-C motif) ligand 2</td></tr><tr><td><i>CLK1</i></td><td>CDC-like kinase 1</td><td><i>CCND1</i></td><td>Cyclin D1</td></tr><tr><td><i>CTGF</i></td><td>Connective tissue growth factor</td><td><i>CYP1B1</i></td><td>Cytochrome P450 subfamily I polypeptide 1</td></tr><tr><td><i>DDIT3/CHOP</i></td><td>DNA-damage-inducible transcript 3</td><td><i>DCK</i></td><td>Deoxycytidine kinase</td></tr><tr><td><i>EIF1/SUI1</i></td><td>Eukaryotic translation initiation factor 1</td><td><i>DIO2</i></td><td>Deiodinase, iodothyronine, type II</td></tr><tr><td><i>GADD45B</i></td><td>Growth arrest and DNA-damage-inducible &#946;</td><td><i>DKFZP686E2158</i></td><td>Hypothetical protein LOC643155</td></tr><tr><td><i>ID1</i></td><td>Inhibitor of DNA binding 1</td><td><i>DKK1</i></td><td>Dickkopf homolog 1 (<i>Xenopus laevis</i>)</td></tr><tr><td><i>ID2B</i></td><td>Striated muscle contraction regulatory prot.</td><td><i>DSCR1</i></td><td>Down syndrome critical region gene 1</td></tr><tr><td><i>IRF7</i></td><td>Interferon regulatory factor 7</td><td><i>EDN1</i></td><td>Endothelin 1</td></tr><tr><td><i>KIF1B</i></td><td>Kinesin family member 1B</td><td><i>F3</i></td><td>Coagulation factor III</td></tr><tr><td><i>KLF6</i></td><td>Kruppel-like factor 6</td><td><i>FGF2</i></td><td>Fibroblast growth factor 2</td></tr><tr><td><i>KLHL24</i></td><td>Kelch-like 24</td><td><i>FST</i></td><td>Follistatin</td></tr><tr><td><i>LOC85028</i></td><td>PNAS-123</td><td><i>G0S2</i></td><td>Putative lymphocyte G0/G1 switch gene</td></tr><tr><td><i>MIR</i></td><td>Myosin regulatory light chain interacting prot.</td><td><i>GABPB2</i></td><td>GA binding protein transcription factor, &#946;2</td></tr><tr><td><i>MT1E</i></td><td>Metallothionein 1E</td><td><i>GBP1</i></td><td>Guanylate binding protein 1</td></tr><tr><td><i>PCMTD1</i></td><td>Protein-L-isoaspartate O-methyltransferase</td><td><i>GBP3</i></td><td>Guanylate binding protein 3</td></tr><tr><td><i>PHLDA1</i></td><td>Pleckstrin homology-like domain family A</td><td><i>GLIPR1</i></td><td>Glioma pathogenesis-related protein</td></tr><tr><td><i>PNPLA8</i></td><td>Patatin-like phospholipase domain 8</td><td><i>GPR19</i></td><td>G protein-coupled receptor 19</td></tr><tr><td><i>RNU2</i></td><td>RNA, U2 small nuclear</td><td><i>GRIK1</i></td><td>Glutamate receptor, ionotropic, kainate 1</td></tr><tr><td><i>SAT</i></td><td>Spermine N1-acetyltransferase</td><td><i>GRO3</i></td><td>GRO3 oncogene</td></tr><tr><td><i>STK31</i></td><td>Serine/threonine kinase 31</td><td><i>IGFBP5</i></td><td>Insulin-like growth factor binding protein 5</td></tr><tr><td><i>TAF9</i></td><td>TAF9 RNA polymerase II</td><td><i>IL7R</i></td><td>Interleukin 7 receptor</td></tr><tr><td><i>TIEG</i></td><td>TGF&#946; inducible early growth response</td><td><i>ISG20L1</i></td><td>Interferon stimulated exonuclease</td></tr><tr><td><i>TXNIP</i></td><td>Thioredoxin interacting protein</td><td><i>LOC57090</i></td><td>HRPAP20 short form</td></tr><tr><td><i>ZBTB1</i></td><td>Zinc finger and BTB domain containing 1</td><td><i>LTV1</i></td><td>LTV1 homolog (<i>S. cerevisiae</i>)</td></tr><tr><td></td><td>cDNA DKFZp564C2063</td><td><i>MAT2A</i></td><td>Methionine adenosyltransferase II, alpha</td></tr><tr><td></td><td></td><td><i>MMP3</i></td><td>Matrix metalloproteinase 3</td></tr><tr><td></td><td></td><td><i>NAV3</i></td><td>Neuron navigator 3</td></tr><tr><td></td><td></td><td><i>NCOA7</i></td><td>Nuclear receptor coactivator 7</td></tr><tr><td></td><td></td><td><i>NOLA1</i></td><td>Nucleolar protein family A, member 1</td></tr><tr><td></td><td></td><td><i>NTF3</i></td><td>Neurotrophin 3</td></tr><tr><td></td><td></td><td><i>NXT1</i></td><td>NUTF-like export factor1</td></tr><tr><td></td><td></td><td><i>PAK1IP1</i></td><td>PAK1 interacting protein 1</td></tr><tr><td></td><td></td><td><i>PLAU</i></td><td>Plasminogen activator, urokinase</td></tr><tr><td></td><td></td><td><i>PPIF</i></td><td>Peptidylprolyl isomerase F (cyclophilin F)</td></tr><tr><td></td><td></td><td><i>PTRH2</i></td><td>Peptidyl-tRNA hydrolase 2</td></tr><tr><td></td><td></td><td><i>PTX3</i></td><td>Pentaxin-related gene</td></tr><tr><td></td><td></td><td><i>RGS20</i></td><td>Regulator of G-protein signalling 20</td></tr><tr><td></td><td></td><td><i>SC4MOL</i></td><td>Sterol-C4-methyl oxidase-like</td></tr><tr><td></td><td></td><td><i>SFRS3</i></td><td>Splicing factor, arginine/serine-rich 3</td></tr><tr><td></td><td></td><td><i>SGNE1</i></td><td>Secretory granule, neuroendocrine protein 1</td></tr><tr><td></td><td></td><td><i>SNK</i></td><td>Serum-inducible kinase</td></tr><tr><td></td><td></td><td><i>STC2</i></td><td>Stanniocalcin 2</td></tr><tr><td></td><td></td><td><i>TNFRSF11B</i></td><td>Tumor necrosis factor receptor 11b (OPG)</td></tr><tr><td></td><td></td><td><i>TRIM16</i></td><td>Tripartite motif-containing 16</td></tr><tr><td></td><td></td><td><i>TSLP</i></td><td>Thymic stromal lymphopoietin</td></tr><tr><td></td><td></td><td></td><td>cDNA FLJ11812 fis, clone HEMBA1006364</td></tr></table>
91270071125c2ef42f20c89866e12102c2627dc42f444b95578836cdd8d4aaef.png
simple
<table><tr><td>Annotation</td><td>Figure 1A*</td><td><i>S. pneumoniae TIGR4</i></td><td><i>S. pneumoniae </i>G54</td><td><i>S. mitis B6</i></td><td><i>S. oralis Uo5</i></td><td><i>S. gordonii V288</i></td><td><i>S. sanguinis SK36</i></td></tr><tr><td>Regulator</td><td>1</td><td>SP1674</td><td>SPG1583</td><td>smi0612</td><td>SOR0560</td><td>SGO0127</td><td>SSA0081</td></tr><tr><td>Hypothetical protein</td><td>2</td><td>-</td><td>-</td><td>smi0610</td><td>SOR0559</td><td>SGO0126</td><td>SSA0080</td></tr><tr><td>N-acetylmannosamine kinase</td><td>3</td><td>SP1675</td><td>SPG1584</td><td>smi0609</td><td>SOR0558</td><td>SGO0125</td><td>SSA0079</td></tr><tr><td>N-acetylneuraminate lyase</td><td>4</td><td>SP1676</td><td>SPG1585</td><td>smi0608</td><td>SOR0557</td><td>SGO0124</td><td>SSA0078</td></tr><tr><td>hypothetical protein</td><td>5</td><td>SP1677</td><td>SPG1586</td><td>smi0607</td><td>SOR0556</td><td>-</td><td>-</td></tr><tr><td>hypothetical protein</td><td>6</td><td>SP1679</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>hypothetical protein</td><td>7</td><td>SP1680</td><td>SPG1588</td><td>smi0606</td><td>SOR0555</td><td>-</td><td>-</td></tr><tr><td><i>satA</i> ABC transporter permease</td><td>8</td><td>SP1681</td><td>SPG1589</td><td>smi0605</td><td>SOR0553</td><td>-</td><td>-</td></tr><tr><td><i>satB</i> ABC transporter permease</td><td>9</td><td>SP1682</td><td>SPG1590</td><td>smi0604</td><td>SOR0552</td><td>-</td><td>-</td></tr><tr><td><i>satC</i> ABC transporter substrate-binding protein</td><td>10</td><td>SP1683</td><td>SPG1591</td><td>smi0603</td><td>SOR0550</td><td>-</td><td>-</td></tr><tr><td>PTS system, IIBC components</td><td>11</td><td>SP1684</td><td>SPG1592</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>NanE, ManAc-6P 2-epimerase</td><td>12</td><td>SP1685</td><td>SPG1593</td><td>smi0602</td><td>SOR0549</td><td>SGO0118</td><td>SSA0071</td></tr><tr><td>oxidoreductase</td><td>13</td><td>SP1686</td><td>SPG1594</td><td>-</td><td>-</td><td>SGO0123</td><td>SSA0077</td></tr><tr><td>NanB neuraminidase</td><td>14</td><td>SP1687</td><td>SPG1595</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>ABC transporter permease</td><td>15</td><td>SP1688</td><td>SPG1596</td><td>-</td><td>-</td><td>SGO0122</td><td>SSA0076</td></tr><tr><td>ABC transporter permease</td><td>16</td><td>SP1689</td><td>SPG1597</td><td>-</td><td>-</td><td>SGO0121</td><td>SSA0075</td></tr><tr><td>ABC transporter substrate-binding protein</td><td>17</td><td>SP1690</td><td>SPG1598</td><td>-</td><td>-</td><td>SGO0120</td><td>SSA0074</td></tr><tr><td>hypothetical protein</td><td>18</td><td>SP1691</td><td>SPG1599</td><td>-</td><td>-</td><td>SGO0119</td><td>SSA0073</td></tr><tr><td>NanA neuraminidase</td><td>19</td><td>SP1693</td><td>SPG1600</td><td>smi0601</td><td>SOR0548</td><td>-</td><td>-</td></tr><tr><td>Acetyl xylan esterase</td><td>20</td><td>SP1694</td><td>SPG1601</td><td>smi0600</td><td>SOR0547</td><td>-</td><td>SSA0070</td></tr></table>
6a76394ab013a24dee75bf7487c8f3597c72a868c624f39384346856d7c1dcea.png
simple
<table><tr><td></td><td></td><td>Age (year)</td><td>BMI (kg/m<sup>2</sup>)</td><td>Size of Tumor (mm)</td><td>Number of Tumor</td></tr><tr><td>Urine HER2/neu</td><td>r</td><td>-0.014</td><td>-0.022</td><td>0.277</td><td>-0.057</td></tr><tr><td></td><td>p</td><td>0.897</td><td>0.843</td><td>0.068</td><td>0.711</td></tr><tr><td>Urinary HER2/neu/ Urinary Creatinine</td><td>r</td><td>0.178</td><td>0.122</td><td>0.108</td><td>-0.070</td></tr><tr><td></td><td>p</td><td>0.105</td><td>0.269</td><td>0.483</td><td>0.649</td></tr><tr><td>Serum HER2/neu</td><td>r</td><td>-0.073</td><td>-0.102</td><td>-0.056</td><td>0.172</td></tr><tr><td></td><td>p</td><td>0.512</td><td>0.363</td><td>0.722</td><td>0.277</td></tr></table>
07e7c484abf4f50640825879b15d51fd79dfb72e226f326489d32e83301a3e5b.png
complex
<table><tr><td>sRNA id</td><td>Start</td><td>End</td><td>Length(nucleotides)</td><td>Flanking gene id</td><td>Strand*</td><td>Expression pattern</td><td>Relative copy numbers</td><td colspan="2">Primers</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Start</td><td>End</td></tr><tr><td>sRNA1</td><td>2840862</td><td>2840921</td><td>~60</td><td>BC2880/BC2881</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>54</td><td>2840862</td><td>2840921</td></tr><tr><td>sRNA2</td><td>1502573</td><td>1502638</td><td>~66</td><td>BC1553/BC1554</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>38</td><td>1502576</td><td>1502635</td></tr><tr><td>sRNA3</td><td>5024909</td><td>5024970</td><td>~62</td><td>BC5122/BC5123</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>36</td><td>5024910</td><td>5024969</td></tr><tr><td>sRNA4</td><td>3372000</td><td>3372189</td><td>~190</td><td>BC3408/BC3409</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>181</td><td>3372130</td><td>3372189</td></tr><tr><td>sRNA5</td><td>4261246</td><td>4261455</td><td>~210</td><td>BC4317/BC4318</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>41</td><td>4261395</td><td>4261454</td></tr><tr><td>sRNA6</td><td>4219221</td><td>4219336</td><td>~116</td><td>BC4271/BC4272</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>56</td><td>4219276</td><td>4219335</td></tr><tr><td>sRNA7</td><td>4040528</td><td>4040740</td><td>~213</td><td>BC4070/BC4071</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>169</td><td>4040679</td><td>4040738</td></tr><tr><td>sRNA8</td><td>525752</td><td>526136</td><td>~385</td><td>BC0547/BC0548</td><td>&gt;&lt;&gt;</td><td>&#8595;&#8593;&#8595;</td><td>142</td><td>526073</td><td>526132</td></tr><tr><td>sRNA9</td><td>1106401</td><td>1106863</td><td>~463</td><td>BC1124/BC1125</td><td>&gt;&lt;&gt;</td><td>&#8595;&#8593;&#8595;</td><td>44</td><td>1106797</td><td>1106856</td></tr><tr><td>sRNA10</td><td>1381925</td><td>1382221</td><td>~297</td><td>BC1419/BC1420</td><td>&gt;&lt;&gt;</td><td>&#8595;&#8593;&#8595;</td><td>183</td><td>1382156</td><td>1382215</td></tr><tr><td>sRNA11</td><td>5372154</td><td>5372598</td><td>~445</td><td>BC5447/BC5448</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>42</td><td>5372540</td><td>5372599</td></tr><tr><td>sRNA12</td><td>4790423</td><td>4791589</td><td>~1167</td><td>BC4864/BC4865</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>19</td><td>4791428</td><td>4791487</td></tr><tr><td>sRNA13</td><td>3802805</td><td>3802907</td><td>~103</td><td>BC3824/BC3825</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>16</td><td>38028445</td><td>3802904</td></tr><tr><td>sRNA14</td><td>3121534</td><td>3121698</td><td>~165</td><td>BC3151/BC3152</td><td>&lt;&gt;&lt;</td><td>&#8595;&#8593;&#8595;</td><td>12</td><td>3121639</td><td>3121698</td></tr></table>
c75814f543e52b3d86271f20f77fa3c079ec3500f8baef4b62bc6194cad5c0da.png
simple
<table><tr><td>Cell line class</td><td>S:MI</td><td>S:MER</td><td>MER:MI</td><td>Significant predictive relationships</td></tr><tr><td>HMEC</td><td>&lt;0.0001**</td><td>0.006**</td><td>0.0120*</td><td>S&#8594;MER, MER&#8594;MI, and S&#8594;MI</td></tr><tr><td>BL</td><td>0.5996</td><td>0.5954</td><td>0.1659</td><td>N/A</td></tr><tr><td>LumB</td><td>0.0041*</td><td>0.4769</td><td>&lt;0.0001**</td><td>MER&#8594;MI, S&#8594;MI</td></tr><tr><td>CL</td><td>0.4827</td><td>0.3758</td><td>0.0051*</td><td>MER&#8594;MI</td></tr><tr><td>Her2E</td><td>0.0706</td><td>0.3090</td><td>0.1309</td><td>N/A</td></tr></table>
32d76eaeff27e75b9bb4aa58e6fa7605d0c11a7c032260eedcb192c03cfa6363.png
simple
<table><tr><td></td><td>cluster &#945;</td><td>hybrid</td><td>cluster &#946;</td></tr><tr><td>Lineage 1</td><td>80</td><td>0</td><td>1</td></tr><tr><td>Lineage 2</td><td>22</td><td>7</td><td>82</td></tr></table>
cd89c283517ebb078cf212b4a1373c7ef988a4539b92fad631c7faf16978ff40.png
simple
<table><tr><td>PCMP Samples</td><td>Sample 1#</td><td>Sample 2#</td><td>Sample 3#</td><td>Sample 4#</td><td>Sample 5#</td><td>Sample 6#</td><td>Sample 7#</td><td>Sample 8#</td><td>Sample 9#</td></tr><tr><td>AP percentage (%)</td><td>0</td><td>2.5</td><td>5</td><td>7.5</td><td>10</td><td>12.5</td><td>15</td><td>17.5</td><td>20</td></tr><tr><td>Heat transfer coefficient (W/m<sup>2</sup>&#183;K)</td><td>2.38</td><td>2.42</td><td>2.59</td><td>2.68</td><td>2.84</td><td>2.98</td><td>3.05</td><td>3.11</td><td>3.24</td></tr></table>
56a07978eb75aeab525da5e6118328f87e1f85ced2d5a3c6488282185e26cb96.png
complex
<table><tr><td>Guliver coding System</td><td rowspan="2">Total sample</td><td rowspan="2">NL</td><td rowspan="2">IT</td><td rowspan="2">UK</td><td rowspan="2">BE</td></tr><tr><td>Category</td></tr><tr><td>Non-verbal behaviour</td><td>69.1</td><td>74.4</td><td>90.0</td><td>59.0</td><td>62.6</td></tr><tr><td>Structuring</td><td>86.0</td><td>94.1</td><td>92.3</td><td>68.5</td><td>89.8</td></tr><tr><td>Summarizing</td><td>84.2</td><td>97.8</td><td>78.0</td><td>71.4</td><td>87.1</td></tr><tr><td>Patient involvement</td><td>71.7</td><td>97.3</td><td>76.7</td><td>71.1</td><td>72.3</td></tr><tr><td>Speaking peculiarities</td><td>27.7</td><td>23.1</td><td>41.7</td><td>17.9</td><td>36.8</td></tr><tr><td>Task-oriented attitude</td><td>95.6</td><td>95.9</td><td>99.6</td><td>92.2</td><td>95.3</td></tr><tr><td>Collecting information</td><td>74.8</td><td>81.7</td><td>89.4</td><td>63.5</td><td>69.5</td></tr><tr><td>Giving information</td><td>91.4</td><td>86.7</td><td>100</td><td>87.9</td><td>92.8</td></tr><tr><td>Providing solution</td><td>95.3</td><td>100</td><td>97.2</td><td>73.3</td><td>97.0</td></tr><tr><td>Affective-oriented attitude</td><td>97.2</td><td>95.3</td><td>100</td><td>95.1</td><td>97.9</td></tr><tr><td>Total</td><td>86.6</td><td>86.7</td><td>93.8</td><td>78.6</td><td>87.8</td></tr></table>
1c4b91f2ae963a7bafdf907aca89697c2b42ff15ef60cd556040649351f8c51c.png
simple
<table><tr><td></td><td>Grade 1</td><td>Grade 2</td><td>Grade 3</td><td>Total</td></tr><tr><td>Group 1</td><td>18 (47.3%)</td><td>15 (39.5%)</td><td>5 (13.2%)</td><td>38</td></tr><tr><td>Group 2</td><td>16 (44.4%)</td><td>13 (36.1%)</td><td>7 (19.4%)</td><td>36</td></tr></table>
20123052d4310f72cb269ee6f60757e45cfec717b4f8565edf59a400e18f1403.png
complex
<table><tr><td rowspan="2">Characteristic</td><td colspan="2">Boys</td><td colspan="2">Girls</td></tr><tr><td>OR</td><td>95% CI</td><td>OR</td><td>95% CI</td></tr><tr><td>Secondhand Smoke Exposure in Household (/None)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>1&#8211;2 Days</td><td>1.00</td><td>0.88&#8211;1.14</td><td>1.41</td><td>1.07&#8211;1.86</td></tr><tr><td>&#8805;3 Days</td><td>1.96</td><td>1.78&#8211;2.17</td><td>2.86</td><td>2.34&#8211;3.49</td></tr><tr><td>Family Smoking Status (/No)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Yes</td><td>1.36</td><td>1.24&#8211;1.49</td><td>1.60</td><td>1.31&#8211;1.95</td></tr><tr><td>Father</td><td>1.16</td><td>1.07&#8211;1.26</td><td>0.92</td><td>0.77&#8211;1.09</td></tr><tr><td>Mother</td><td>1.84</td><td>1.52&#8211;2.22</td><td>2.46</td><td>1.87&#8211;3.24</td></tr><tr><td>Siblings</td><td>2.07</td><td>1.83&#8211;2.35</td><td>2.49</td><td>2.01&#8211;3.10</td></tr><tr><td>Grandparents</td><td>1.20</td><td>1.02&#8211;1.42</td><td>2.59</td><td>2.02&#8211;3.31</td></tr><tr><td>Friends&#8217; Smoking Status (/No)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Some</td><td>3.64</td><td>2.98&#8211;4.44</td><td>6.51</td><td>4.40&#8211;9.64</td></tr><tr><td>Most/all</td><td>22.82</td><td>18.70&#8211;27.85</td><td>81.43</td><td>55.49&#8211;119.51</td></tr><tr><td>Witnessed Smoking at School (/No)</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Yes</td><td>1.94</td><td>1.77&#8211;2.12</td><td>1.90</td><td>1.58&#8211;2.28</td></tr></table>
99c9829b3e807589228e0a478030ebbae3d35c57fc2aa0eda1ff6b9195848a5e.png
complex
<table><tr><td rowspan="3">Variable</td><td rowspan="2">Placebo (<i>n</i> = 25)</td><td colspan="6">Telotristat ethyl</td></tr><tr><td colspan="3">250 mg tid (<i>n</i> = 25)</td><td colspan="3">500 mg tid (<i>n</i> = 25)</td></tr><tr><td>Mean (s.d.)</td><td>Mean (s.d.)</td><td><i>P</i></td><td>95% CL</td><td>Mean (s.d.)</td><td><i>P</i></td><td>95% CL</td></tr><tr><td colspan="8">BM frequency</td></tr><tr><td> Change from baseline in BM frequency averaged over 12 weeks, counts/day</td><td>0.05 (0.33)</td><td>&#8722;0.45 (0.69)</td><td>&#8722;</td><td>&#8722;</td><td>&#8722;0.60 (0.72)</td><td>&#8722;</td><td>&#8722;</td></tr><tr><td> Arithmetic mean treatment difference</td><td>&#8722;</td><td>&#8722;0.50</td><td>&#8722;</td><td>&#8722;0.81 to &#8722;0.19</td><td>&#8722;0.65</td><td>&#8722;</td><td>&#8722;0.96 to &#8722;0.33</td></tr><tr><td> Hodges&#8211;Lehmann estimator</td><td>&#8722;</td><td>&#8722;0.45</td><td>0.004</td><td>&#8722;0.72 to &#8722;0.17</td><td>&#8722;0.54</td><td>&lt;0.001</td><td>&#8722;0.79 to &#8722;0.25</td></tr><tr><td colspan="8">Stool consistency</td></tr><tr><td> Change from baseline in stool consistency averaged over 12 weeks (Bristol Stool Form scale)</td><td>0.01 (0.41)</td><td>&#8722;0.20 (0.70)</td><td>&#8211;</td><td>&#8211;</td><td>&#8722;0.60 (0.86)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Arithmetic mean treatment difference</td><td>&#8722;</td><td>&#8722;0.20</td><td>&#8211;</td><td>&#8722;0.53 to 0.13</td><td>&#8722;0.60</td><td>&#8211;</td><td>&#8722;0.99 to &#8722;0.22</td></tr><tr><td> Hodges&#8211;Lehmann estimator</td><td>&#8722;</td><td>&#8722;0.20</td><td>0.09</td><td>&#8722;0.45 to 0.02</td><td>&#8722;0.39</td><td>0.009</td><td>&#8722;0.82 to &#8722;0.12</td></tr><tr><td colspan="8">Flushing</td></tr><tr><td> Change from baseline in daily cutaneous flushing episodes averaged over 12 weeks, counts/day</td><td>&#8722;0.33 (1.22)</td><td>&#8722;0.06 (0.98)</td><td>&#8211;</td><td>&#8211;</td><td>0.11 (2.10)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Arithmetic mean treatment difference</td><td>&#8722;</td><td>0.27</td><td>&#8211;</td><td>&#8722;0.36 to 0.90</td><td>0.45</td><td>&#8211;</td><td>&#8722;0.53 to 1.42</td></tr><tr><td> Hodges&#8211;Lehmann estimator</td><td>&#8722;</td><td>0.11</td><td>0.67</td><td>&#8722;0.17 to 0.61</td><td>0.02</td><td>0.58</td><td>&#8722;0.28 to 0.62</td></tr><tr><td colspan="8">Abdominal pain</td></tr><tr><td> Change from baseline in abdominal pain averaged over 12 weeks, 11-point numeric rating scale</td><td>&#8722;0.06 (0.78)</td><td>&#8722;0.23 (0.97) </td><td>&#8211;</td><td>&#8211;</td><td>0.03 (0.77)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Arithmetic mean treatment difference</td><td>&#8722;</td><td>&#8722;0.17</td><td>&#8211;</td><td>&#8722;0.67 to 0.33</td><td>0.09</td><td>&#8211;</td><td>&#8722;0.35 to 0.53</td></tr><tr><td> Hodges&#8211;Lehmann estimator</td><td>&#8722;</td><td>0.06</td><td>0.61</td><td>&#8722;0.42 to 0.33</td><td>0.14</td><td>0.66</td><td>&#8722;0.39 to 0.51</td></tr><tr><td colspan="8">Rescue short-acting SSA use</td></tr><tr><td> Change from baseline in rescue short-acting SSA use averaged over 12 weeks, counts/day</td><td>&#8722;0.01 (0.14)</td><td>&#8722;0.07 (0.35)</td><td>&#8211;</td><td>&#8211;</td><td>0.01 (0.10)</td><td>&#8211;</td><td>&#8211;</td></tr><tr><td> Arithmetic mean treatment difference</td><td>&#8722;</td><td>&#8722;0.05</td><td>&#8211;</td><td>&#8722;0.20 to 0.10</td><td>0.02</td><td>&#8211;</td><td>&#8722;0.05 to 0.09</td></tr><tr><td> Hodges&#8211;Lehmann estimator</td><td>&#8722;</td><td>0.00</td><td>0.45</td><td>0.00&#8211;0.00</td><td>0.000</td><td>0.98</td><td>0.00&#8211;0.00</td></tr></table>
f92cd5d011a2ef0b1071124804f603c29631d9a8d72005b4c22c7c16f1636a67.png
simple
<table><tr><td>Performance Statistics</td><td>Total(<i>n</i> = 1053)</td><td>Initial surgery-MR interval &#8804; 36 months(<i>n</i> = 709)</td><td>Initial surgery-MR interval &gt; 36 months(<i>n</i> = 344)</td><td><i>p</i> value</td></tr><tr><td>Cancer detection rate for MRI<sup>a</sup></td><td>6.7 (7/1053)</td><td>1.4 (1/709)</td><td>17.4 (6/344)</td><td>0.006</td></tr><tr><td>Abnormal interpretation rate for MRI</td><td>84/1053 (8.0%)<sup>c</sup></td><td>51/709 (7.2%)</td><td>33/344 (9.6%)</td><td>0.184</td></tr><tr><td>Cancer detection rate for intramammary lesions<sup>b</sup></td><td>3.8 (4/1053)</td><td>1.41 (1/709)</td><td>8.7 (3/344)</td><td>0.105</td></tr><tr><td>Abnormal interpretation rate for intramammary lesions</td><td>76/1053 (7.2%)</td><td>49/709 (6.9%)</td><td>27/344 (7.8%)</td><td>0.612</td></tr><tr><td>PPV<sub>1</sub></td><td>4/76 (5.3%)</td><td>1/49 (2.0%)</td><td>3/27 (11.1%)</td><td>0.125</td></tr><tr><td>PPV<sub>3</sub></td><td>3/19 (15.8%)</td><td>1/10 (10.0%)</td><td>2/9 (22.2%)</td><td>0.582</td></tr><tr><td>Sensitivity</td><td>3/4 (75.0%)</td><td>1/1 (100%)</td><td>2/3 (66.7%)</td><td>&gt; 0.999</td></tr><tr><td>Specificity</td><td>1031/1049 (98.3%)</td><td>698/708 (98.6%)</td><td>333/341 (97.6%)</td><td>0.199</td></tr></table>
d2df24024962d4ecb7fc1034267c9387755e791ead3ad2984879ec05b7fe78ae.png
complex
<table><tr><td></td><td>Men</td><td>Women</td><td></td></tr><tr><td></td><td colspan="2">Change from baseline value</td><td><i>P</i> value</td></tr><tr><td>HR (beats/min)</td><td>47 &#177; 12</td><td>38 &#177; 10</td><td>0.20</td></tr><tr><td>MAP (mmHg)</td><td>&#8722;31 &#177; 9</td><td>&#8722;33 &#177; 8</td><td>0.45</td></tr><tr><td>SAP (mmHg)</td><td>&#8722;54 &#177; 7</td><td>&#8722;48 &#177; 8</td><td>0.29</td></tr><tr><td>DAP (mmHg)</td><td>&#8722;18 &#177; 5</td><td>&#8722;18 &#177; 7</td><td>0.78</td></tr><tr><td>SV (mL)</td><td>&#8722;57 &#177; 8</td><td>&#8722;41 &#177; 4</td><td>0.006</td></tr><tr><td>Q (L/min)</td><td>&#8722;1.6 &#177; 0.7</td><td>&#8722;1.4 &#177; 0.4</td><td>0.32</td></tr><tr><td>TPR (mmHg/L/min)</td><td>6.2 &#177; 3.9</td><td>9.2 &#177; 1.8</td><td>0.10</td></tr><tr><td>RRIHF (Vagal Index)</td><td>1229 &#177; 1118</td><td>1155 &#177; 769</td><td>0.44</td></tr><tr><td>BRS</td><td>16.4 &#177; 3.8</td><td>18.7 &#177; 5.3</td><td>0.53</td></tr><tr><td>SAP-MSNA coherence (arbitrary units)</td><td>0.05 &#177; 0.14</td><td>&#8722;0.39 &#177; 0.28</td><td>0.03</td></tr><tr><td>SAP LF (mmHg<sup>2</sup>)</td><td>27.5 &#177; 19</td><td>16.2 &#177; 6</td><td>0.09</td></tr></table>
8e298d72c64af258baa9af87aae515ec7961a4043e23b0974a05823bf2c48a92.png
simple
<table><tr><td>Gene Title and Abbreviation (The GENE Database)</td><td>Percent Change </td></tr><tr><td>OPRM1, 1 opioid receptor, mu 1</td><td>+1294</td></tr><tr><td>TP73, 2 tumor protein p73</td><td>+938</td></tr><tr><td>KCND1, 3 potassium voltage-gated channel, Shal-related subfamily, member 1</td><td>+845</td></tr><tr><td>SLC8A2, 4 solute carrier family 8 (sodium/calcium exchanger), member 2</td><td>+737</td></tr><tr><td>CNTNAP2, 5 contactin associated protein-like 2</td><td>+581</td></tr><tr><td>STMN3, 6 stathmin-like 3</td><td>+500</td></tr><tr><td>LPHN3, 7 latrophilin 3 </td><td>+494</td></tr><tr><td>ANGPT1, 8 angiopoietin 1</td><td>+487</td></tr><tr><td>SYN3, 9 synapsin III</td><td>+478</td></tr><tr><td>DPP6,10 dipeptidyl-peptidase 6</td><td>+448</td></tr><tr><td>PITX3, 221 paired-like homeodomain 3</td><td>&#8722;541</td></tr><tr><td>NOTCH3, 222 notch 3</td><td>&#8722;547</td></tr><tr><td>DLGAP1, 223 discs, large homolog-associated protein 1</td><td>&#8722;547</td></tr><tr><td>SLIT1, 224 slit homolog 1</td><td>&#8722;553</td></tr><tr><td>BSN, 225 bassoon (presynaptic cytomatrix protein)</td><td>&#8722;563</td></tr><tr><td>CELSR1, 226 cadherin, EGF LAG seven-pass G-type receptor 1</td><td>&#8722;647</td></tr><tr><td>CACNB4, 227 calcium channel, voltage-dependent, beta 4 subunit</td><td>&#8722;672</td></tr><tr><td>NDN, 228 necdin homolog (mouse)</td><td>&#8722;729</td></tr><tr><td>EDNRB, 229 endothelin receptor type B</td><td>&#8722;768</td></tr><tr><td>CHRM2, 230 cholinergic receptor, muscarinic 2</td><td>&#8722;1049</td></tr></table>
073de18bfcab82ee45d5b27f77030bf99a6d86c8fcec4c50fcd3de10a51fc411.png
complex
<table><tr><td rowspan="2">Prognostic factor/parameter</td><td rowspan="2">N evt/N pts</td><td colspan="2">Univariate analysis (n=108)</td><td colspan="2">Multivariate analysis (n=99)</td></tr><tr><td>HR [95% CI]</td><td><i>p</i>-Value (Wald)</td><td>HR [95% CI]</td><td><i>p</i>-Value (Wald)</td></tr><tr><td>Smoker status</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Never</td><td>7/11</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> Former/current</td><td>76/95</td><td>1.8 [0.9-4.0]</td><td>0.12</td><td>2.1 [0.8-5.1]</td><td>0.11</td></tr><tr><td>Performance Status</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 0-1</td><td>65/85</td><td>1</td><td></td><td>1</td><td></td></tr><tr><td> &gt;1</td><td>16/19</td><td>1.8 [1.0-3.1]</td><td>0.039</td><td>1.6 [0.9-2.9]</td><td>0.12</td></tr><tr><td>Primary size tumor</td><td>80/103</td><td>1.0 [0.99-1.01]</td><td>0.70</td><td>1.0 [0.99-1.01]</td><td>0.97</td></tr><tr><td>Adrenal metastasis</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>49/91</td><td>1</td><td>0.21</td><td>1</td><td>0.01</td></tr><tr><td> Yes</td><td>11/17</td><td>1.5 [0.8-2.9]</td><td></td><td>2.2 [1.2-4.0]</td><td></td></tr><tr><td>Liver metastasis</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No</td><td>51/93</td><td>1</td><td>0.38</td><td>1</td><td>0.67</td></tr><tr><td> Yes</td><td>9/15</td><td>1.4 [0.7-2.8]</td><td></td><td>1.2 [0.6-2.2]</td><td></td></tr><tr><td>Coarse (2.2)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Entropy</td><td>84/108</td><td>1.2 [0.7-2.1]</td><td>0.59</td><td>-</td><td>-</td></tr><tr><td>Coarse (2.8)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Entropy</td><td>84/108</td><td>1.2 [0.8-1.8]</td><td>0.37</td><td>-</td><td>-</td></tr><tr><td>Coarse (3.3)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Entropy</td><td>84/108</td><td>1.2 [0.9 - 1.6]</td><td>0.18</td><td>1.1 [0.8-1.5]</td><td>0.65</td></tr></table>
8e5e8afeff06649aa22209969495d941eb7f46392f243ce483971cc866d9b803.png
complex
<table><tr><td></td><td></td><td colspan="5">Relative risk reduction</td></tr><tr><td></td><td></td><td>20%</td><td>24%</td><td>28%</td><td>32%</td><td>35%</td></tr><tr><td>Control event rate</td><td>25%</td><td>0.49</td><td>0.68</td><td>0.84</td><td>0.93</td><td>0.97</td></tr><tr><td></td><td>27%</td><td>0.54</td><td>0.73</td><td>0.87</td><td>0.95</td><td>0.98</td></tr><tr><td></td><td>30%</td><td>0.61</td><td>0.80</td><td>0.92</td><td>0.98</td><td>0.99</td></tr><tr><td></td><td>33%</td><td>0.68</td><td>0.85</td><td>0.95</td><td>0.99</td><td>1.00</td></tr><tr><td></td><td>35%</td><td>0.72</td><td>0.89</td><td>0.99</td><td>1.00</td><td>1.00</td></tr></table>
e463722e0d61154e0b10b52afa6eec580f0fc6f9a8a7aa29f0f63778d3acdd23.png
simple
<table><tr><td> </td><td>Predicted change in hazard for one unit change in variable</td><td>Significance (<i>P</i>)</td></tr><tr><td>HADS anxiety</td><td>1.012 (0.39&#8211;2.58)</td><td>0.98</td></tr><tr><td>HADS depression</td><td>0.82 (0.22&#8211;3.05)</td><td>0.76</td></tr><tr><td>PANAS negative affect</td><td>1.07 (0.33&#8211;3.47)</td><td>0.90</td></tr><tr><td>Mood rating scale</td><td>1.20 (0.48&#8211;3.0)</td><td>0.68</td></tr><tr><td>FACT C FW</td><td>0.56 (0.16&#8211;1.89)</td><td>0.81</td></tr><tr><td>FACT C AC</td><td>0.37 (0.16&#8211;0.89)</td><td>0.02</td></tr><tr><td>TNM</td><td>4.35 (1.93&#8211;9.8)</td><td>&lt;0.001</td></tr></table>
6bddfae7be93ecfa85b7b28dd77ad2927644c8071c63bd48da8898650db1e5e9.png
simple
<table><tr><td> </td><td>N</td><td>Minimum</td><td>Maximum</td><td>Mean</td><td>Std. Deviation</td></tr><tr><td>IL- 17 B</td><td>24</td><td>18.258</td><td>31.605</td><td>23.63281</td><td>3.553243</td></tr><tr><td>IL-10 B</td><td>24</td><td>.00</td><td>112.43</td><td>13.8533</td><td>28.72131</td></tr><tr><td>IL-17 P</td><td>24</td><td>21.009</td><td>33.020</td><td>24.97380</td><td>3.595384</td></tr><tr><td>IL-10 P</td><td>24</td><td>1.75</td><td>229.83</td><td>60.1112</td><td>59.13965</td></tr><tr><td>WBC</td><td>24</td><td>2.3</td><td>30.6</td><td>10.296</td><td>5.5273</td></tr><tr><td>RBC</td><td>24</td><td>3.16</td><td>5.17</td><td>3.9788</td><td>.53680</td></tr><tr><td>HCT</td><td>24</td><td>28.4</td><td>46.5</td><td>36.192</td><td>4.7277</td></tr><tr><td>PLT</td><td>24</td><td>87</td><td>658</td><td>283.71</td><td>117.411</td></tr><tr><td>HB</td><td>24</td><td>9</td><td>16</td><td>12.02</td><td>1.675</td></tr><tr><td>GR%</td><td>24</td><td>43.5</td><td>93.8</td><td>71.912</td><td>10.7272</td></tr><tr><td>MONO%</td><td>24</td><td>.8</td><td>30.6</td><td>9.846</td><td>6.6490</td></tr><tr><td>LYMPH%</td><td>24</td><td>1.4</td><td>32.1</td><td>17.308</td><td>7.5535</td></tr><tr><td>AGE</td><td>24</td><td>37</td><td>74</td><td>60.42</td><td>10.270</td></tr><tr><td>GENDER</td><td>24</td><td>1</td><td>2</td><td>1.63</td><td>.495</td></tr><tr><td>AGEgroup</td><td>24</td><td>1</td><td>3</td><td>2.50</td><td>.659</td></tr><tr><td>primary1</td><td>24</td><td>1</td><td>2</td><td>1.63</td><td>.495</td></tr><tr><td>TYPE_3_UN</td><td>24</td><td>1</td><td>3</td><td>2.04</td><td>.624</td></tr><tr><td>chemo1yes</td><td>24</td><td>0</td><td>1</td><td>.58</td><td>.504</td></tr><tr><td>Valid N (listwise)</td><td>24</td><td> </td><td> </td><td> </td><td> </td></tr></table>
20a6135d7fa210053e50836a51f31cc37bec988b3ff31510821e29a02f5860ac.png
simple
<table><tr><td>Author, Year [Reference]</td><td>Study Design</td><td>StudyPopulationParticipantsAgeBMIHealth Status</td><td>Intervention and Doses</td><td>Duration Weeks</td><td>Observed Effects</td></tr><tr><td>Pol, 2013 [28]</td><td>Meta-analysis of 26 RCTs</td><td>2060 M/F18&#8211;70 years18.5&#8211;35.8 kg/m<sup>2</sup>Healthy</td><td>Whole grain (mean dose: 84.1 g/day)vs. refined grain</td><td>2&#8211;16</td><td>= BW&#8595; body fat: &#8722;0.48%vs.refined grain</td></tr><tr><td>Kim, 2016 [29]</td><td>Meta-analysis of 21 RCTs</td><td>940 M/F47&#8211;57 years27.6&#8211;31.4 kg/m<sup>2</sup>Metabolic syndrome</td><td>Dietary pulses (mean dose: 142 g/day)vs. control</td><td>4&#8211;12</td><td>&#8595; BW: &#8722;0.34 kgvs.control</td></tr><tr><td>Mytton, 2014 [30]</td><td>Meta-analysis of 8 RCTs</td><td>1026 M/F30&#8211;75 years23.7&#8211;37.8 kg/m<sup>2</sup>Healthy</td><td>High fruit and vegetablesvs. low fruit and vegetables consumption(mean dose difference in vegetables and fruit consumptionbetween arms 133 g/day)</td><td>4&#8211;52</td><td>&#8595; BW: &#8722;0.54 kgvs.low fruit and vegetables</td></tr><tr><td>Thompson, 2017 [31]</td><td>Meta-analysis of 12 RCTs</td><td>609 M/F20&#8211;70 years25&#8211;35 kg/m<sup>2</sup>Healthy</td><td>Soluble fibre supplementation (mean dose: 18.5 g/day)vs. control</td><td>2&#8211;17</td><td>&#8595; BMI: &#8722;0.84 kg&#8595; BW: &#8722;2.52 kg&#8595; body fat: &#8722;0.41%vs.control</td></tr></table>
01948ae250c97faaf24303c7d359e2314a9e1d1246d5543bb168ad3037a5f85e.png
simple
<table><tr><td>Year</td><td>High-risk owned dogs</td><td>Pets</td></tr><tr><td></td><td>Positive/Total (%)</td><td>Positive/Total (%)</td></tr><tr><td>2011</td><td>7/196 (3.6)</td><td>8/811 (1.0)</td></tr><tr><td>2012</td><td>10/502 (2.0)</td><td>9/561 (1.6)</td></tr><tr><td>2013</td><td>10/415 (2.4)</td><td>&#8211;</td></tr><tr><td>2014</td><td>3/209 (1.4)</td><td>&#8211;</td></tr><tr><td>2015</td><td>4/200 (2.0)</td><td>&#8211;</td></tr><tr><td>2016</td><td>3/200 (1.5)</td><td>&#8211;</td></tr><tr><td>Total<sup>a</sup></td><td>37/1,722 (2.1)</td><td>17/1,372 (1.2)</td></tr></table>
a112902abfbe0ebc2adcae64cfa2bf09ca52e21f20b1a682ea67d996dbb8cc0b.png
complex
<table><tr><td>Assembler</td><td>Number of scaffolds</td><td>Longest scaffold (kb)</td><td>Longest scaffold corr. (kb)</td><td>N50 (kb)</td><td>Err.</td><td>N50 corr. (kb)</td><td>LAP</td></tr><tr><td colspan="8"><i>Human chromosome 14</i>, starting from Velvet assembly</td></tr><tr><td> Before</td><td>1,081</td><td>4,628</td><td>263</td><td>1,190</td><td>9,156</td><td>27</td><td>&#8722;138.765779</td></tr><tr><td> After</td><td>1,634</td><td>1,046</td><td>265</td><td>347</td><td>8,049</td><td>27</td><td>&#8722;138.632657</td></tr><tr><td> REAPR</td><td>17,727</td><td>153</td><td>81</td><td>36</td><td>4,607</td><td>14</td><td>&#8722;162.869192</td></tr><tr><td colspan="8"><i>Human chromosome 14</i>, starting from ALLPATHS assembly</td></tr><tr><td> Before</td><td>129</td><td>81,640</td><td>14,918</td><td>81,640</td><td>34</td><td>7,652</td><td>&#8722;111.288806</td></tr><tr><td> After</td><td>139</td><td>81,640</td><td>14,918</td><td>81,640</td><td>33</td><td>7,652</td><td>&#8722;111.287938</td></tr><tr><td> REAPR</td><td>858</td><td>977</td><td>146</td><td>190</td><td>4,230</td><td>17</td><td>&#8722;168.024865</td></tr></table>
0c30c092c376aefc9f2daee32d3e146163d61bf02fd6cfe6593927d71e9b102d.png
complex
<table><tr><td></td><td>*1/*1 (n<i> </i>=<i> </i>229)</td><td>*1/*2 + *2/*2 (n<i> </i>=<i> </i>148)</td><td><i>P</i>&#8208;value</td></tr><tr><td>Lesion vessel number</td><td></td><td></td><td>NS</td></tr><tr><td>1 (n, %)</td><td>55 (24%)</td><td>39 (26.4%)</td><td></td></tr><tr><td>2 (n, %)</td><td>69 (30.1%)</td><td>43 (29.1%)</td><td></td></tr><tr><td>3 (n, %)</td><td>105 (45.9%)</td><td>66 (44.6%)</td><td></td></tr><tr><td colspan="4">Lesion vessel</td></tr><tr><td>LM (n, %)</td><td>23 (10%)</td><td>27 (18.2%)</td><td>.033</td></tr><tr><td>LAD (n, %)</td><td>184 (80.3%)</td><td>124 (83.8%)</td><td>NS</td></tr><tr><td>LCX (n, %)</td><td>146 (63.8%)</td><td>90 (60.8%)</td><td>NS</td></tr><tr><td>RCA (n, %)</td><td>167 (72.9%)</td><td>98 (66.2%)</td><td>NS</td></tr><tr><td>Revascularization (n, %)</td><td>187 (81.7%)</td><td>130 (87.8%)</td><td>NS</td></tr><tr><td>Revascularization vessel &gt;1 (n, %)</td><td>112 (48.9%)</td><td>81 (54.7%)</td><td>NS</td></tr><tr><td>TIMI3 grade after PCI (n, %)</td><td>219 (95.6%)</td><td>139 (93.9%)</td><td>NS</td></tr></table>
585dfeabbbc24436b2d00e138a97dc781b3588696f202abd6affc92c29f11e39.png
simple
<table><tr><td>Variable</td><td>Possible score range</td><td>Group</td><td>Number</td><td>Baseline Mean (SD)</td><td>Number</td><td>Month 3 Mean (SD)</td><td>Mean change (SD)</td><td><i>t</i>-test (<i>p</i>-value) <sup>a</sup></td></tr><tr><td>Self-management knowledge<sup>b</sup></td><td>0&#8211;27</td><td>Intervention</td><td>51</td><td>21.1 (2.8)</td><td>51</td><td>23.1 (2.7)</td><td>2.0 (3.4)</td><td>.337</td></tr><tr><td></td><td></td><td>Control</td><td>49</td><td>19.4 (3.0)</td><td>47</td><td>21.1 (2.5)</td><td>1.7 (2.6)</td><td></td></tr><tr><td>Self-efficacy for HF self-management<sup>c</sup></td><td>0&#8211;100</td><td>Intervention</td><td>51</td><td>44.9 (24.7)</td><td>51</td><td>59.7 (17.3)</td><td>14.8 (26.0)</td><td>.034</td></tr><tr><td></td><td></td><td>Control</td><td>49</td><td>49.2 (22.9)</td><td>47</td><td>53.8 (24.0)</td><td>5.2 (25.5)</td><td></td></tr><tr><td>Patient activation (PAM Rasch scaled scores) <sup>d</sup></td><td>0&#8211;100</td><td>Intervention</td><td>51</td><td>57.3 (19.2)</td><td>50</td><td>69.1 (16.7)</td><td>11.7 (21.3)</td><td>.069</td></tr><tr><td></td><td></td><td>Control</td><td>48</td><td>56.6 (18.6)</td><td>47</td><td>61.4 (18.2)</td><td>5.7 (18.5)</td><td></td></tr><tr><td>Self-management strategies (RSCB) <sup>e</sup></td><td>0&#8211;145</td><td>Intervention</td><td>50</td><td>86.8 (19.3)</td><td>51</td><td>115.7 (19.6)</td><td>28.9 (23.0)</td><td>&lt;.0005</td></tr><tr><td></td><td></td><td>Control</td><td>49</td><td>91.9 (19.9)</td><td>47</td><td>97.6 (22.6)</td><td>5.6 (22.3)</td><td></td></tr></table>
79e8eac811b2a1f5719e02ec70367f7e8ee136637cc51a752192f1fdc7f63dc8.png
complex
<table><tr><td>Repeat type</td><td colspan="3">Structured</td><td colspan="3">Unstructured</td></tr><tr><td></td><td>RONN</td><td>DISOPRED</td><td>IUPRED</td><td>RONN</td><td>DISOPRED</td><td>IUPRED</td></tr><tr><td>E</td><td>3</td><td>13</td><td>10</td><td>97</td><td>87</td><td>90</td></tr><tr><td>P</td><td>6</td><td>5</td><td>5</td><td>94</td><td>95</td><td>95</td></tr><tr><td>A</td><td>32</td><td>23</td><td>63</td><td>68</td><td>77</td><td>37</td></tr><tr><td>S</td><td>4</td><td>6</td><td>16</td><td>96</td><td>94</td><td>84</td></tr><tr><td>L</td><td>100</td><td>97</td><td>100</td><td>0</td><td>3</td><td>0</td></tr><tr><td>G</td><td>11</td><td>8</td><td>14</td><td>89</td><td>92</td><td>86</td></tr><tr><td>Q</td><td>13</td><td>3</td><td>14</td><td>87</td><td>97</td><td>86</td></tr></table>
cf762ac10a009531ba1257fbd813396054efb756f18b4fa31ea0b86fbdab4662.png
complex
<table><tr><td></td><td>Setting</td><td colspan="6">Results of simulations</td></tr><tr><td>Methods (Effect measures)</td><td><i>&#946;</i><sub>X</sub></td><td>Mean of estimates (Ratio scale)</td><td>Bias (Log scale)</td><td>Empirical standard error</td><td>Mean squared error</td><td>Mean standard error</td><td>Coverage (%)</td></tr><tr><td>SCCS (IRR)</td><td>log(1.0)</td><td>0.99</td><td>-0.0125</td><td>0.1354</td><td>0.0185</td><td>0.1335</td><td>95.1</td></tr><tr><td>CCO (OR)</td><td></td><td>1.00</td><td>-0.0005</td><td>0.2084</td><td>0.0434</td><td>0.2116</td><td>96.1</td></tr><tr><td>SSA (ASR)</td><td></td><td>0.99</td><td>-0.0005</td><td>0.2373</td><td>0.0563</td><td>0.2454</td><td>96.3</td></tr><tr><td>SCCS (IRR)</td><td>log(3.0)</td><td>2.99</td><td>-0.0030</td><td>0.0791</td><td>0.0063</td><td>0.0777</td><td>94.7</td></tr><tr><td>CCO (OR)</td><td></td><td>3.04</td><td>0.0121</td><td>0.18</td><td>0.0309</td><td>0.1732</td><td>94.8</td></tr><tr><td>SSA (ASR)</td><td></td><td>3.04</td><td>0.0119</td><td>0.2016</td><td>0.0408</td><td>0.2003</td><td>95.2</td></tr><tr><td>SCCS (IRR)</td><td>log(10.0)</td><td>9.98</td><td>-0.0019</td><td>0.0438</td><td>0.0019</td><td>0.0446</td><td>95.5</td></tr><tr><td>CCO (OR)</td><td></td><td>10.30</td><td>0.0295</td><td>0.1663</td><td>0.0285</td><td>0.1604</td><td>94.4</td></tr><tr><td>SSA (ASR)</td><td></td><td>9.97</td><td>-0.0026</td><td>0.1834</td><td>0.0336</td><td>0.1817</td><td>94.7</td></tr></table>
fda82e4d7263a1359ee3a36cd925dd498c0f2d17ff27a5e707fe0b09ad37df85.png
simple
<table><tr><td>mRNA</td><td>Primers<sup>a</sup></td></tr><tr><td>MMP-13</td><td>Fw: 5'-TTGGTCAGATGTGACACCTCRv: 5'-ATCGGGAAGCATAAAGTGGC</td></tr><tr><td>Cathepsin K</td><td>Fw: 5'-AGGTGGATGAAATCTCTCGGRv: 5'-TTCTTGAGTTGGCCCTCCAG</td></tr><tr><td>5-LOX</td><td>Fw: 5'-TGCGTTCCAGTGACTTCCACRv: 5'-CTCTGCACCATCTGCACGTG</td></tr><tr><td>ADAMTS-4</td><td>Fw: 5'-TACTACTATGTGCTGGAGCCRv: 5'-AGTGACCACATTGTTGTATCC</td></tr><tr><td>ADAMTS-5</td><td>Fw: 5'-GGCATCATTCATGTGACACRv: 5'-GCATCGTAGGTCTGTCCTG</td></tr><tr><td>GAPDH</td><td>Fw: 5'-AGGCTGTGGGCAAGGTCATCRv: 5'-AAGGTGGAAGAGTGGGTGTC</td></tr></table>
86ea0e98ce038fc35fa42fa866b200ae597b4f2f6a616f97cbfa7adc4657a33c.png
simple
<table><tr><td>Population</td><td>GO ID</td><td>Gene ontology term</td><td>Genes under GO term</td><td>Related environmental stressor(s)</td><td>Reference</td></tr><tr><td>Kuroilers</td><td>GO:0060584</td><td>Regulation of prostaglandin-endoperoxide synthase activity</td><td>EDN2, EDN1</td><td>Oxidative stress/Pathogen</td><td>Lee et al. 2007 [89]</td></tr><tr><td></td><td>GO:0007631</td><td>Feeding behavior</td><td>HCRTR2, HTR1B, GRIN1, NPY1R, ASIP</td><td>Nutrient stress</td><td>UniProt [67], Jenuth 2000 [69, 77]</td></tr><tr><td></td><td>GO:0032693</td><td>Negative regulation of interleukin-10 production</td><td>TRIB2, IL-12B</td><td>Pathogen</td><td>UniProt [67], Jenuth 2000 [69, 77]</td></tr><tr><td></td><td>GO:0051341</td><td>Regulation of oxidoreductase activity</td><td>ACVR2A, EDN2, EDN1, SNCA</td><td>Oxidative stress/Pathogen</td><td>UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89]</td></tr><tr><td></td><td>GO:0007618</td><td>Mating</td><td>ACVR2A, SERPINE2, GRIN1</td><td>Survival Behavior</td><td>UniProt [67], Jenuth 2000 [69, 77]</td></tr><tr><td></td><td>GO:0016627</td><td>Oxidoreductase activity, acting on the CH-CH group of donors</td><td>IVD, CPOX, ACAD9, DHCR24</td><td>Oxidative/Environmental Stress</td><td>UniProt [67], Jenuth 2000 [69, 77], Lee et al. 2007 [89]</td></tr><tr><td></td><td>GO:0006950</td><td>Response to stress</td><td>ENTPD1, ETFDH, WNT5A CHID1, RBBP5, NEDD4, NSMCE2, GLP1R, STX2, LEAP2, RAB23, DEAF1, TNFSF11, PPP2R5C, DRD4, ZC3HAV1, CDH8, PPAP2B, GTF2H5, MCPH1, EDN1, FAM175B, GCLM, JAK1, UBXN2A, MID1, BATF, CPEB2, IL12B, PIK3AP1, SOX2, SNCA, CITED2, CHAC1, DTL, HIPK3, NOS1, STT3B, PDIA4, SBNO2, NUAK1, CDC7, SERPINE2, ULK1, MASP2, WFS1, DHCR24, PRKD1</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Puvadolpirod et al. 2000 [48], Li et al. 2011 [70], Yen et al. 2014 [90]</td></tr><tr><td></td><td>GO:0080134</td><td>Regulation of response to stress</td><td>WNT5A, CHID1, PIK3AP1, IL12B, STX2, SNCA, HIPK3, TNFSF11, ZC3HAV1, PPAP2B, SBNO2, NUAK1, MCPH1, EDN1, SERPINE2, ULK1, WFS1, MID1</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Puvadolpirod et al. 2000 [48], Li et al., 2011, Yen et al., 2014</td></tr><tr><td></td><td>GO:0033554</td><td>Cellular response to stress</td><td>WNT5A, RBBP5, BATF, CPEB2, NEDD4, NSMCE2, SNCA, CHAC1, CITED2, DTL, HIPK3, RAB23, TNFSF11, PPP2R5C, PDIA4, GTF2H5, NUAK1, FAM175B, EDN1, CDC7, ULK1, WFS1, UBXN2A, MID1, PRKD1</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Puvadolpirod et al. 2000 [48]</td></tr><tr><td></td><td>GO:0045859</td><td>Regulation of protein kinase activity</td><td>TNFSF11, DRD4, WNT5A, TGFBR2, RAPGEF2, PDGF, PIK3CA, KIAA1199, LATS2, IL12B, EDN1, PAQR3, SNCA, GTPBP4, HIPK3</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Jenuth 2000 [69, 77]</td></tr><tr><td></td><td>GO:0003100</td><td>Regulation of systemic arterial blood pressure by endothelin</td><td>EDN2, EDN1</td><td>Oxidative/Metabolic Stress</td><td>Endemann et al. 2004 [20], Gomez et al. 2007 [21]</td></tr><tr><td></td><td>GO:0048010</td><td>Vascular endothelial growth factor receptor signaling pathway</td><td>FIGF, NEDD4, GRB10, PRKD1</td><td>Oxidative/Metabolic Stress</td><td>Koch et al., 2012 [57]</td></tr><tr><td></td><td>GO:0004674</td><td>Protein serine/threonine kinase activity</td><td>CDC42BPB, DCLK1, TGFBR3, TGFBR2, PRKCA, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, HIPK3, VRK1, PRKD1</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Evans et al. 2002 [46], Perkins et al. 2007 [55], Salminen et al. 2008 [87], Tam et al., 2012 [88]</td></tr><tr><td></td><td>GO:0009628</td><td>Response to abiotic stimulus</td><td>GPR65, GRIN1, CASP8, IL12B, CPEB2, SOX2, NEDD4, TNFRSF8, CITED2, DTL, ER81, NOS1, DEAF1, CNGA2, CDH8, MME, GTF2H5, HR1B, SERPINE2, EDN1, FAM175B</td><td>Oxidative/Metabolic/Environmental Stress</td><td>Mashaly et al. 2004 [92], Mujahid et al. 2005 [16]</td></tr><tr><td></td><td>GO:0004672</td><td>Protein kinase activity</td><td>CDC42BPB, DCLK1, PRKCA, HIPK3, VRK1, ROR1, TRIB2, TGFBR3, TGFBR2, LATS2, ACVR2A, NUAK1, CDC7, ULK1, CDC2L1, PEAK1, JAK1, RPS6KC1, PRKD1</td><td>Oxidative/Metabolic/Environmental Stress</td><td>UniProt [67], Jenuth 2000 [69, 77]</td></tr></table>
b0a0ca8a28e28a04cb11345d10850bb389359be438496ced9bd1775966bc517f.png
simple
<table><tr><td>Source</td><td><i>F</i> ratio</td><td><i>p</i></td></tr><tr><td>Method</td><td>7.377</td><td>0.013</td></tr><tr><td>Method &#215; group</td><td>0.373</td><td>0.547</td></tr><tr><td>Task</td><td>35.697</td><td>0.000</td></tr><tr><td>Task &#215; group</td><td>0.030</td><td>0.865</td></tr><tr><td>Hemisphere</td><td>0.310</td><td>0.583</td></tr><tr><td>Hemisphere &#215; group</td><td>0.692</td><td>0.414</td></tr><tr><td>Method &#215; task</td><td>4.838</td><td>0.039</td></tr><tr><td>Method &#215; task &#215; group</td><td>0.005</td><td>0.945</td></tr><tr><td>Method &#215; hemisphere</td><td>0.047</td><td>0.831</td></tr><tr><td>Method &#215; hemisphere &#215; group</td><td>0.042</td><td>0.839</td></tr><tr><td>Task &#215; hemisphere</td><td>0.035</td><td>0.853</td></tr><tr><td>Task &#215; hemisphere &#215; group</td><td>0.207</td><td>0.653</td></tr><tr><td>Method &#215; task &#215; hemisphere</td><td>0.009</td><td>0.924</td></tr><tr><td>Method &#215; task &#215; hemisphere &#215; group</td><td>0.123</td><td>0.730</td></tr></table>
2a30fa2f96392860b4f606ebe018f130370c2e15201d428a8221204f10570aa2.png
simple
<table><tr><td>Solvents</td><td>SC16-Lu</td><td>TC18-Lu</td><td>TC16-Lu</td><td>TC14-Lu</td><td>TC12-Lu</td></tr><tr><td>Acetone</td><td>I</td><td>I</td><td>G (1.5)</td><td>I</td><td>PS</td></tr><tr><td>Aniline</td><td>S</td><td>G (2.0)</td><td>G (2.0)</td><td>G (1.5)</td><td>PS</td></tr><tr><td>Toluene</td><td>PS</td><td>PS</td><td>I</td><td>PS</td><td>PS</td></tr><tr><td>Pyridine</td><td>S</td><td>S</td><td>G (2.0)</td><td>S</td><td>S</td></tr><tr><td>Isopropanol</td><td>PS</td><td>G (2.5)</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Cyclopentanone</td><td>PS</td><td>G (2.0)</td><td>G (1.5)</td><td>PS</td><td>PS</td></tr><tr><td>Cyclohexanone</td><td>PS</td><td>PS</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Nitrobenzene</td><td>S</td><td>G (2.0)</td><td>G (2.0)</td><td>G (2.0)</td><td>PS</td></tr><tr><td><i>n</i>-Butanol</td><td>PS</td><td>G (2.5)</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Ethanolamine</td><td>G (2.0)</td><td>PS</td><td>I</td><td>S</td><td>PS</td></tr><tr><td><i>n</i>-Butyl acrylate</td><td>PS</td><td>PS</td><td>S</td><td>PS</td><td>PS</td></tr><tr><td>1,4-Dioxane</td><td>PS</td><td>G (2.5)</td><td>G (2.0)</td><td>S</td><td>PS</td></tr><tr><td>Petroleum ether</td><td>S</td><td>G (2.0)</td><td>S</td><td>S</td><td>PS</td></tr><tr><td>Ethyl acetate</td><td>PS</td><td>PS</td><td>S</td><td>PS</td><td>PS</td></tr><tr><td>Dichloromethane</td><td>PS</td><td>S</td><td>S</td><td>S</td><td>S</td></tr><tr><td>THF</td><td>I</td><td>PS</td><td>S</td><td>PS</td><td>PS</td></tr><tr><td>DMF</td><td>PS</td><td>G (2.0)</td><td>G (1.5)</td><td>G (1.5)</td><td>S</td></tr><tr><td>DMSO</td><td>G (2.5)</td><td>PS</td><td>I</td><td>G (2.0)</td><td>PS</td></tr><tr><td>Ethanol</td><td>PS</td><td>G (2.0)</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Benzene</td><td>PS</td><td>PS</td><td>I</td><td>S</td><td>PS</td></tr><tr><td>Tetrachloromethane</td><td>PS</td><td>PS</td><td>PS</td><td>S</td><td>S</td></tr><tr><td>Acetonitrile</td><td>PS</td><td>PS</td><td>PS</td><td>PS</td><td>PS</td></tr><tr><td>Methanol</td><td>PS</td><td>PS</td><td>S</td><td>PS</td><td>PS</td></tr><tr><td><i>n</i>-Pentanol</td><td>PS</td><td>G (2.5)</td><td>G (2.0)</td><td>PS</td><td>PS</td></tr><tr><td>Cyclopentanol</td><td>PS</td><td>G (2.0)</td><td>S</td><td>PS</td><td>PS</td></tr><tr><td>Formaldehyde (aq.)</td><td>PS</td><td>PS</td><td>PS</td><td>PS</td><td>PS</td></tr></table>
237a23175dded2f1092b0704a81f7d577ff0b282fd4c554ca3e2ee4c50f9950f.png
complex
<table><tr><td> </td><td>Biocatalyst</td><td>S/B</td><td>RS%</td><td>Xyl%</td><td>Glc%</td><td>Useful results</td></tr><tr><td rowspan="2">1</td><td rowspan="2">TL-xylanase</td><td rowspan="2">3.3</td><td rowspan="2">23.5</td><td rowspan="2">2.26</td><td rowspan="2">8.6</td><td>xylobiose 3.3 g/L</td></tr><tr><td>pentasaccharide 1 (Figure 2), 2 g/L</td></tr><tr><td>2</td><td>TM-xylanase</td><td>2.6</td><td>38</td><td>0</td><td>0</td><td>-</td></tr><tr><td>3</td><td>CFE-TT</td><td>3.5</td><td>90</td><td>19.2</td><td>16.9</td><td>-</td></tr><tr><td>4</td><td>CFE-TT</td><td>1.2</td><td>100</td><td>28.6</td><td>6.8</td><td>-</td></tr><tr><td>5</td><td>CFE-TT</td><td>3.5</td><td>20</td><td>8.7</td><td>7.8</td><td>tetrasaccharide 2 (Figure 2) 2.64 g/L</td></tr><tr><td>6</td><td>CFE-TN</td><td>1.2</td><td>75</td><td>40.5</td><td>15.2</td><td>see Figure 3</td></tr><tr><td>7</td><td>ES-GTM1b</td><td>13.5</td><td>73.5</td><td>26.5</td><td>0</td><td>see Figure 3</td></tr><tr><td>8</td><td>ES-GTM1a</td><td>36.3</td><td>63.1</td><td>9.85</td><td>0</td><td>see Figure 3</td></tr><tr><td> </td><td> </td><td> </td><td colspan="4">Comment</td></tr><tr><td>9</td><td>TM-xylanase</td><td>7.7</td><td colspan="4">Formation of mono and dixylosylated acceptor</td></tr><tr><td>10</td><td>CFE-TN</td><td>1.2</td><td colspan="4">Formation of mono and dixylosylated acceptor</td></tr><tr><td>11</td><td>ES-GTM1</td><td>13.5</td><td colspan="4">Formation of mono, di and trixylosylated acceptor</td></tr><tr><td>12</td><td>CFE-TT</td><td>3.5</td><td colspan="4">Formation of mono and dixylosylated acceptor</td></tr></table>
6a85f3b98cba0a627f1325dfb0b61309c1c29bb51a681a8472acf2782cf3ec27.png
complex
<table><tr><td></td><td>Reason for hysterectomy</td><td></td><td>Number of women with vaginal bleeding</td><td>Odds ratio (95% CI)</td></tr><tr><td rowspan="6">Supracervical abdominal hysterectomy</td><td rowspan="2">Fibroids</td><td>Yes</td><td>16</td><td>0.66 (0.16, 2.71)*</td></tr><tr><td>No</td><td>3</td><td></td></tr><tr><td rowspan="2">Heavy bleeding</td><td>Yes</td><td>11</td><td>1.28 (0.49, 3.35)*</td></tr><tr><td>No</td><td>8</td><td></td></tr><tr><td rowspan="2">Pain and/or endometriosis</td><td>Yes</td><td>5</td><td>1.37 (0.43, 4.32)*</td></tr><tr><td>No</td><td>14</td><td></td></tr><tr><td rowspan="6">Supracervical laparoscopic hysterectomy</td><td rowspan="2">Fibroids</td><td>Yes</td><td>33</td><td>0.47 (0.23, 0.93)*</td></tr><tr><td>No</td><td>24</td><td></td></tr><tr><td rowspan="2">Heavy bleeding</td><td>Yes</td><td>41</td><td> 4.07 (1.32, 12.57)*</td></tr><tr><td>No</td><td>16</td><td></td></tr><tr><td rowspan="2">Pain and/or endometriosis</td><td>Yes</td><td>23</td><td>0.41 (0.20, 0.85)*</td></tr><tr><td>No</td><td>34</td><td></td></tr></table>
fa25f3bc99b3f07260d9c69edcff8a5bd4c6c036271eaeccba439571587b2366.png
simple
<table><tr><td>Module</td><td>Module hub genes</td><td>Module membership</td><td>LPS log2FC</td><td>DE FDR</td></tr><tr><td>module I</td><td><i>BIRC3</i></td><td>0.97</td><td>1.26</td><td>1.89e-12</td></tr><tr><td>module I</td><td><i>VPS37A</i></td><td>0.95</td><td>0.53</td><td>3.97e-9</td></tr><tr><td>module I</td><td><i>STARD13</i></td><td>0.94</td><td>0.80</td><td>1.01e-4</td></tr><tr><td>module I</td><td><i>SOD2</i></td><td>0.94</td><td>1.75</td><td>8.83e-16</td></tr><tr><td>module I</td><td><i>SLC1A2</i></td><td>0.94</td><td>2.83</td><td>3.62e-18</td></tr><tr><td>module I</td><td><i>ARHGEF3</i></td><td>0.94</td><td>0.53</td><td>3.39e-8</td></tr><tr><td>module I</td><td><i>TTC25</i></td><td>0.94</td><td>0.84</td><td>5.30e-8</td></tr><tr><td>module I</td><td><i>SLC39A14</i></td><td>0.93</td><td>1.80</td><td>2.80e-12</td></tr><tr><td>module I</td><td><i>ENSECAG00000002023,</i> superoxide dismutase</td><td>0.93</td><td>1.79</td><td>5.69e-16</td></tr><tr><td>module I</td><td><i>TREX1</i></td><td>0.93</td><td>0.85</td><td>2.25e-7</td></tr><tr><td>module II</td><td><i>VAT1</i></td><td>0.95</td><td>&#8722;1.13</td><td>1.68e-16</td></tr><tr><td>module II</td><td><i>SDC3</i></td><td>0.94</td><td>&#8722;2.27</td><td>1.16e-9</td></tr><tr><td>module II</td><td><i>FCGRT</i></td><td>0.94</td><td>&#8722;1.39</td><td>1.42e-10</td></tr><tr><td>module II</td><td><i>SLC46A1</i></td><td>0.94</td><td>&#8722;1.80</td><td>8.21e-18</td></tr><tr><td>module II</td><td><i>NAAA</i></td><td>0.94</td><td>&#8722;0.94</td><td>2.53e-20</td></tr><tr><td>module II</td><td><i>CSF1R</i></td><td>0.93</td><td>&#8722;1.54</td><td>1.43e-11</td></tr><tr><td>module II</td><td><i>MAN2B1</i></td><td>0.93</td><td>&#8722;0.44</td><td>5.77e-10</td></tr><tr><td>module II</td><td><i>ARRB1</i></td><td>0.92</td><td>&#8722;1.03</td><td>3.19e-9</td></tr><tr><td>module II</td><td><i>GAMT</i></td><td>0.92</td><td>&#8722;2.40</td><td>3.77e-19</td></tr><tr><td>module II</td><td><i>S100A4</i></td><td>0.92</td><td>&#8722;1.10</td><td>4.29e-12</td></tr></table>
59af4aeaf7b6e182f31bf732260bdabf5b8f6a9632d4b9b1092bdbc32a5063be.png
simple
<table><tr><td>Comparator</td><td>Correlation [95% CI] with UCEIS</td><td>Correlation [95% CI] with Modified Baron Score<sup>a</sup></td></tr><tr><td>Full MCS<sup>+</sup> [including endoscopy]</td><td>0.86 [0.83, 0.88]</td><td>N/A<sup>b</sup></td></tr><tr><td>Partial MCS [excluding endoscopy]</td><td>0.82 [0.79, 0.85]</td><td>0.77 [0.61, 0.88]</td></tr><tr><td>Stool frequency subscore</td><td>0.76 [0.72, 0.80]</td><td>0.73 [0.53, 0.85]</td></tr><tr><td>Rectal bleeding subscore</td><td>0.82 [0.78, 0.85]</td><td>0.74 [0.54, 0.85]</td></tr><tr><td>Both stool frequency and rectal bleeding</td><td>0.81 [0.77, 0.84]</td><td>0.77 [0.58, 0.87]</td></tr><tr><td>Patient functional assessment subscore</td><td>0.76 [0.71, 0.79]</td><td>0.52 [0.24, 0.72]</td></tr><tr><td>Modified Baron score<sup>a</sup></td><td>0.78 [0.74, 0.81]</td><td>-</td></tr></table>
55265840356d74c790ec41d061e9b8737e4e53ae1a35b01c85cc8dbb0ece513e.png
simple
<table><tr><td></td><td>Vials with FA detectedn (%)</td><td>Vials without FAn (%)</td></tr><tr><td>Infundibulae or surface structures on sections</td><td>376 (72.6)</td><td>94 (18.1)</td></tr><tr><td>No infundibulae or surface structures on sections</td><td>0 (0.0)</td><td>48 (9.3)</td></tr></table>
58a50a61712fb6bfd8738fb1156ef24cd39df3f1d86c8a8c589abda6d3e77a0e.png
complex
<table><tr><td rowspan="2">Image number</td><td colspan="3">Proposed method (<i>e</i><sub>1</sub>)</td><td colspan="3">Method proposed by Zhang (<i>e</i><sub>2</sub>)</td></tr><tr><td>7</td><td>14</td><td>20</td><td>7</td><td>14</td><td>20</td></tr><tr><td>1</td><td>0.050</td><td>0.021</td><td>0.011</td><td>0.041</td><td>0.034</td><td>0.012</td></tr><tr><td>2</td><td>0.047</td><td>0.032</td><td>0.027</td><td>0.025</td><td>0.029</td><td>0.039</td></tr><tr><td>3</td><td>0.061</td><td>0.011</td><td>0.034</td><td>0.037</td><td>0.028</td><td>0.019</td></tr><tr><td>4</td><td>0.103</td><td>0.028</td><td>0.018</td><td>0.031</td><td>0.051</td><td>0.027</td></tr><tr><td>5</td><td>0.032</td><td>0.036</td><td>0.012</td><td>0.028</td><td>0.047</td><td>0.014</td></tr><tr><td>6</td><td>0.098</td><td>0.040</td><td>0.019</td><td>0.029</td><td>0.013</td><td>0.009</td></tr><tr><td>7</td><td>0.057</td><td>0.035</td><td>0.017</td><td>0.037</td><td>0.018</td><td>0.015</td></tr><tr><td>8</td><td>0.046</td><td>0.022</td><td>0.020</td><td>0.035</td><td>0.024</td><td>0.020</td></tr><tr><td>9</td><td>0.039</td><td>0.023</td><td>0.025</td><td>0.041</td><td>0.015</td><td>0.034</td></tr><tr><td>10</td><td>0.049</td><td>0.039</td><td>0.020</td><td>0.022</td><td>0.022</td><td>0.009</td></tr><tr><td>Average error</td><td>0.058</td><td>0.0287</td><td>0.0203</td><td>0.0326</td><td>0.0281</td><td>0.0198</td></tr></table>
551074ee442b4da02e38bad7a5d84f1ee6de4f446fa2b31d8604900c81356e38.png
simple
<table><tr><td>Variable</td><td>Number</td><td>%</td></tr><tr><td>Age, mean &#177; SD</td><td>69.0 &#177; 10.2</td><td> </td></tr><tr><td>Sex</td><td> </td><td> </td></tr><tr><td> Male</td><td>159</td><td>70.7</td></tr><tr><td> Female</td><td>66</td><td>29.3</td></tr><tr><td>Histology</td><td> </td><td> </td></tr><tr><td> Adenocarcinoma</td><td>139</td><td>61.5</td></tr><tr><td> Squamous cell</td><td>67</td><td>30.1</td></tr><tr><td> NSCLC-NOS</td><td>10</td><td>4.4</td></tr><tr><td> Pleomorphic</td><td>5</td><td>2.2</td></tr><tr><td> Adenosquamous</td><td>4</td><td>1.8</td></tr><tr><td>Pathological stage</td><td> </td><td> </td></tr><tr><td> IA</td><td>78</td><td>34.5</td></tr><tr><td> IB</td><td>53</td><td>23.9</td></tr><tr><td> IIA</td><td>23</td><td>10.2</td></tr><tr><td> IIB</td><td>24</td><td>10.6</td></tr><tr><td> IIIA</td><td>36</td><td>15.9</td></tr><tr><td> IIIB/IV</td><td>11</td><td>4.9</td></tr></table>
bd4f98437065e6233f5ba62aeb94c828072e6abcac23bf38b3c52e1a55f9e132.png
complex
<table><tr><td rowspan="2"> </td><td colspan="2">Total population</td><td>Consumers only</td><td rowspan="2" colspan="3">Percentiles of intake among consumers</td></tr><tr><td colspan="2">N = 8,861</td><td>n = 2,310</td></tr><tr><td>Gender</td><td>Mean &#177; SE</td><td>Pct.</td><td>Mean &#177; SE</td><td>25th &#177; SE</td><td>50th &#177; SE</td><td>75th &#177; SE</td></tr><tr><td>Combined</td><td>50.3 &#177; 1.8</td><td>23.8</td><td>210.0 &#177; 3.8</td><td>109.4 &#177; 3.0</td><td>468.6 &#177; 4.7</td><td>259.3 &#177; 6.8</td></tr><tr><td> Male</td><td>59.2 &#177; 2.7<sup>a</sup></td><td>24.5</td><td>235.6 &#177; 5.3<sup>a</sup></td><td>118.3 &#177; 4.1</td><td>192.2 &#177; 2.0</td><td>286.9 &#177; 8.3</td></tr><tr><td> Female</td><td>41.4 &#177; 2.1<sup>b</sup></td><td>23.1</td><td>177.4 &#177; 5.0<sup>b</sup></td><td>94.6 &#177; 3.8</td><td>147.9 &#177; 7.4</td><td>227.7 &#177; 7.7</td></tr></table>
ee274ad530b54de04a371851dd62cbb79b7c09d58859f74c56aa2784f614c495.png
complex
<table><tr><td rowspan="2">Sample <sup>a</sup></td><td colspan="5">Molar Composition <sup>b</sup> (Relative %, mol/mol)</td><td colspan="2">Molar Ratio <sup>c</sup></td></tr><tr><td>Ara</td><td>Gal</td><td>Glc</td><td>Xyl</td><td>GlcA</td><td>GlcA/Xyl</td><td>Ara/Xyl</td></tr><tr><td>H<sub>2</sub></td><td>11.25 &#177; 0.2</td><td>4.60 &#177; 0.1</td><td>22.01 &#177; 0.1</td><td>58.30 &#177; 0.0</td><td>3.59 &#177; 0.1</td><td>0.06</td><td>0.19</td></tr><tr><td>H<sub>24</sub></td><td>6.48 &#177; 0.1</td><td>0.59 &#177; 0.0</td><td>2.87 &#177; 0.2</td><td>86.93 &#177; 0.0</td><td>3.30 &#177; 0.0</td><td>0.03</td><td>0.07</td></tr></table>
7c0b26e8fc87352967ca7fb189db6f12c2f889db8749aae5931b62a6cb3c8e56.png
complex
<table><tr><td>Microorganisms</td><td>Isolation Sites</td><td>Applications</td><td>Enzyme</td><td>Reference</td></tr><tr><td><i>Pseudoalteromonas haloplanktis</i></td><td>Antarctica</td><td>Starch conversion; detergent</td><td>Amylase Endo-amylase</td><td>[106]</td></tr><tr><td><i>Zunongwangia profunda</i></td><td>Deep-sea, China</td><td>Starch conversion; detergent</td><td>Alpha-amylase</td><td>[107]</td></tr><tr><td><i>Martelella mediterranea</i></td><td>Lake Martel, Spain</td><td>cellulose conversion; detergent</td><td>Beta-glucosidase</td><td>[22]</td></tr><tr><td><i>Desulfotalea psychrophila</i></td><td>Marine sediments, Antarctica</td><td>Agriculture; food; pharmaceutical industries</td><td>Esterase</td><td>[108]</td></tr><tr><td><i>Pseudoalteromonas haloplanktis</i></td><td>Marine Antarctic</td><td>Detergent</td><td>Lipase</td><td>[98]</td></tr><tr><td><i>Psychrobacter</i> sp. wp37</td><td>Deep-sea sediments, West Pacific</td><td>Detergent</td><td>Lipase</td><td>[109]</td></tr><tr><td>Microorganisms</td><td colspan="2">EPS-Structure and Chemical Composition <sup>1</sup></td><td>Applications and Activity</td><td>Reference</td></tr><tr><td><i>Pseudomonas</i> sp. ID1</td><td colspan="2">Carbohydrates 33.8% (Glc 17.0%, Gal 8.6%, Fuc 8.2%)/Uronic acids 2.4%/Proteins 2.8%</td><td>Cryo-protection and emulsifying activities</td><td>[110]</td></tr><tr><td><i>Pseudomonas</i> strain CAM025</td><td colspan="2">Glc/GalA/Rha/Gal Molar ratios: 1:0.5:0.1:0.08</td><td>Cryo-protection and trace metal binding</td><td>[110]</td></tr></table>
c52942c59800e1e1458fc050a25d1076d68fd853687556befa2079deda66c754.png
simple
<table><tr><td>Indicator</td></tr><tr><td>A Ratio of native Dutch within total population: both parents were born in the Netherlands</td></tr><tr><td>B Ratio of Moroccan origin within total population: person or at least one parent was born in Morocco</td></tr><tr><td>C Ratio of Turkish origin within total population: person or at least one parent was born in Turkey</td></tr><tr><td>D Ratio of Surinamese origin within total population: person or at least one parent was born in Surinam</td></tr><tr><td>E Ratio of Antillean origin within total population: person or at least one parent was born in the Netherlands Antilles</td></tr></table>
965a1204bfa8274f8aa00b0364e36fa0afa7cf10a225ba767755f42f4ddf02cd.png
simple
<table><tr><td></td><td>C</td><td>C + WGP</td><td>HF</td><td>HF + WGP</td></tr><tr><td>Glucose in plasma (mg/dL)</td><td>94.8 &#177; 1.8</td><td>88.3 &#177; 3.0</td><td>104.3 &#177; 2.8*</td><td>91. &#177; 2.84</td></tr><tr><td>Triglycerides in plasma (mg/mL)</td><td>92.4 &#177; 6.8</td><td>108.8 &#177; 4.2</td><td>140.7 &#177; 11.2*</td><td>122.1 &#177; 7.8</td></tr><tr><td>Insulin in plasma (&#956;U/mL)</td><td>7.6 &#177; 1.5</td><td>5.8 &#177; 0.6</td><td>912.2 &#177; 1.3*</td><td>8.9 &#177; 0.7</td></tr><tr><td>Systolic arterial pressure (mmHg)</td><td>108.8 &#177; 4.4</td><td>110.6 &#177; 2.1</td><td>115.0 &#177; 1.7</td><td>112.2 &#177; 1.8</td></tr><tr><td>Body weight (g)</td><td>515.8 &#177; 22.6</td><td>519.1 &#177; 17.9</td><td>514.0 &#177; 22.4</td><td>528.9 &#177; 21.8</td></tr><tr><td>Heart weight (g)</td><td>1.43 &#177; 0.05</td><td>1.46 &#177; 0.06</td><td>1.50 &#177; 0.05</td><td>1.56 &#177; 0.09</td></tr></table>
81274611a5afc73b18c413e91bb9388a408184e4a0e45b78d874073f03a2ffe3.png
complex
<table><tr><td>Variable</td><td>Group on-pump (<i>n</i> = 146)</td><td>Group off-pump (<i>n</i> = 92)</td><td><i>P</i> Value</td></tr><tr><td colspan="4">Clinical demographics</td></tr><tr><td> Age (y)</td><td>65 &#177; 8</td><td>63 &#177; 9</td><td>0.0749</td></tr><tr><td> Female sex</td><td>25 (17.1%)</td><td>12(13.0%)</td><td>0.398</td></tr><tr><td colspan="4">Coronary risk factors</td></tr><tr><td> Hypertension</td><td>95(65.1%)</td><td>59(64.1%)</td><td>0.883</td></tr><tr><td> Diabetes</td><td>122(83.6%)</td><td>76(82.6%)</td><td>0.080</td></tr><tr><td> Hyperlipidemia</td><td>64(43.8%)</td><td>55(59.8%)</td><td>0.017</td></tr><tr><td> Smoking</td><td>67(45.9%)</td><td>41(44.6%)</td><td>0.842</td></tr><tr><td> Peripheral vascular disease</td><td>28(19.2%)</td><td>15(16.6%)</td><td>0.575</td></tr><tr><td> Previous renal impairment</td><td>8(5.5%)</td><td>4(4.3%)</td><td>0.698</td></tr><tr><td> Cerebrovascular accident</td><td>3(2.1%)</td><td>13(14.1%)</td><td>0.000</td></tr><tr><td> COPD</td><td>6(4.1%)</td><td>22(23.9%)</td><td>0.000</td></tr><tr><td> Calcified ascending aorta</td><td>4(2.7%)</td><td>45(48.9%)</td><td>0.000</td></tr><tr><td colspan="4">Cardiac profile</td></tr><tr><td> Previous myocardial infarction</td><td>93(63.7%)</td><td>55(62.2%)</td><td>0.544</td></tr><tr><td> Unstable angina</td><td>106(72.6%)</td><td>68(73.9%)</td><td>0.824</td></tr><tr><td> previous PCI</td><td>23(15.8%)</td><td>15(16.3%)</td><td>0.910</td></tr><tr><td> Mean ejection fraction</td><td>0.58 &#177; 0.12</td><td>0.56 &#177; 0.11</td><td>0.1974</td></tr><tr><td>Poor ejection fraction(&lt;0.35)</td><td>15(10.3%)</td><td>9(9.8%)</td><td>0.902</td></tr><tr><td> Left main disease</td><td>29(19.8%)</td><td>17(18.5%)</td><td>0.792</td></tr><tr><td> RCA Critical stenosis &gt; 90%</td><td>81(55.5%)</td><td>89(96.7%)</td><td>0.000</td></tr><tr><td> Number of diseased vessels</td><td>3.5 &#177; 0.5</td><td>3.4 &#177; 0.6</td><td>0.1689</td></tr></table>
ea05a163c528a5df64164aa77faff34999192099e3366825cf614106079e98a1.png
complex
<table><tr><td rowspan="2">Characteristics</td><td>Total population</td></tr><tr><td>n = 3807</td></tr><tr><td colspan="2"><i>Gender</i></td></tr><tr><td>Male</td><td>42.1 %</td></tr><tr><td colspan="2"><i>Age (years)</i></td></tr><tr><td>Mean (SD)</td><td>78 (7.68)</td></tr><tr><td>Range</td><td>65&#8211;102</td></tr><tr><td colspan="2"><i>Number of chronically used drugs</i></td></tr><tr><td>Median (IQR)</td><td>9 (7&#8211;11)</td></tr><tr><td>Mean (SD)</td><td>9.54 (3.40)</td></tr><tr><td>Range</td><td>5&#8211;27</td></tr><tr><td colspan="2"><i>Number of DRPs</i></td></tr><tr><td>Median (IQR)</td><td>2 (1&#8211;4)</td></tr><tr><td>Mean (SD)</td><td>3.00 (2.26)</td></tr><tr><td>Range</td><td>1&#8211;26</td></tr></table>
58a2797d5d03f854f208dd760699e1bd47f9be6ca55471894a18e25d379b5598.png
complex
<table><tr><td></td><td colspan="2">(-)crystal packing</td><td colspan="5">biological interactions(+)</td></tr><tr><td><i>support </i>level</td><td colspan="7">range of support ratios</td></tr><tr><td></td><td>-INF</td><td>-2</td><td>1</td><td>2</td><td>3</td><td>&gt; = 4</td><td>INF</td></tr><tr><td></td><td>-INF</td><td>(-2.5,-1.5]</td><td>(-1.5,1.5)</td><td>[1.5,2.5)</td><td>[2.5,3.5)</td><td>[3.5,7.5)</td><td>INF</td></tr><tr><td>2</td><td>13</td><td>0</td><td>152</td><td>0</td><td>0</td><td>0</td><td>1144</td></tr><tr><td>3</td><td>0</td><td>3</td><td>0</td><td>38</td><td>0</td><td>0</td><td>207</td></tr><tr><td>4</td><td>0</td><td>0</td><td>0</td><td>0</td><td>13</td><td>0</td><td>40</td></tr><tr><td>&gt; = 5</td><td>0</td><td>0</td><td>0</td><td>1</td><td>7</td><td>6</td><td>23</td></tr><tr><td>Total</td><td>13</td><td>3</td><td>152</td><td>39</td><td>20</td><td>6</td><td>1414</td></tr></table>
ddc696e49d9b5992c46b17678caa479643a03a5daa53e45eb47467be617f10fc.png
simple
<table><tr><td></td><td>Total group (n = 270)</td><td>Subgroup (n = 141)</td></tr><tr><td>Haemoglobin (g/dl)</td><td>13.1 &#177; 0.9</td><td>13.2 &#177; 0.9</td></tr><tr><td>Haematocrit (%)</td><td>39.2 &#177; 2.7</td><td>39.2 &#177; 2.8</td></tr><tr><td>Mean Corpuscular Volume (fl.)</td><td>87.2 &#177; 5.0</td><td>86.9 &#177; 5.0</td></tr><tr><td>Serum Ferritin (ng/ml)</td><td>25.1 &#177; 21.3</td><td>25.5 &#177; 16.9</td></tr><tr><td>Serum Transferrin (mg/dl)</td><td>307.5 &#177; 54.1</td><td>311.5 &#177; 56.7</td></tr><tr><td>Serum iron (&#956;g/dl)</td><td>81.7 &#177; 37.5</td><td>80.0 &#177; 36.</td></tr><tr><td>Transferrin saturation (%)</td><td>19.4 &#177; 10.2</td><td>18.8 &#177; 8.7</td></tr></table>
97c04dff93eb76784078ded1b8bb8a3829687f91425a40324959203c28ab55c4.png
simple
<table><tr><td>Layers</td><td>Attacks</td></tr><tr><td>Physical layer</td><td>Jamming, Node tampering</td></tr><tr><td>Link layer/medium access control</td><td>Collision, exhaustion, and unfairness</td></tr><tr><td>Network and routing layer</td><td>Neglect and greed, homing, misdirection, spoofing, replaying, routing-control traffic or clustering messages</td></tr><tr><td>Transport layer</td><td>Flooding and De-synchronization</td></tr><tr><td>Application layer</td><td>Overwhelming sensors, reprogramming attack</td></tr></table>
d1f36bf7f7510d77cca26057d2ad87d6e41395e7bddd8b31e2e82777e549cac3.png
complex
<table><tr><td></td><td colspan="3">ADC: SUVmax</td><td colspan="3">SQC: SUVmax</td></tr><tr><td>Factor</td><td>Low</td><td>High</td><td><i>P</i>value</td><td>Low</td><td>High</td><td><i>P</i>value</td></tr><tr><td>Pleural invasion</td><td></td><td></td><td>0.027</td><td></td><td></td><td>0.064</td></tr><tr><td> No</td><td>19</td><td>19</td><td></td><td>17</td><td>9</td><td></td></tr><tr><td> Yes</td><td>2</td><td>12</td><td></td><td>1</td><td>5</td><td></td></tr><tr><td>Vascular invasion</td><td></td><td></td><td>0.042</td><td></td><td></td><td>0.735</td></tr><tr><td> No</td><td>17</td><td>16</td><td></td><td>9</td><td>6</td><td></td></tr><tr><td> Yes</td><td>4</td><td>15</td><td></td><td>9</td><td>8</td><td></td></tr><tr><td>Nodal status</td><td></td><td></td><td>0.016</td><td></td><td></td><td>0.365</td></tr><tr><td> N0</td><td>21</td><td>23</td><td></td><td>16</td><td>10</td><td></td></tr><tr><td> N1 + 2</td><td>0</td><td>8</td><td></td><td>2</td><td>4</td><td></td></tr><tr><td>Cox-2 expression</td><td></td><td></td><td>0.001</td><td></td><td></td><td>0.473</td></tr><tr><td> Negative</td><td>13</td><td>5</td><td></td><td>12</td><td>7</td><td></td></tr><tr><td> Positive</td><td>8</td><td>26</td><td></td><td>6</td><td>7</td><td></td></tr><tr><td>Ki-67 expression</td><td></td><td></td><td>0.011</td><td></td><td></td><td>0.087</td></tr><tr><td> Negative</td><td>15</td><td>11</td><td></td><td>11</td><td>4</td><td></td></tr><tr><td> Positive</td><td>6</td><td>20</td><td></td><td>7</td><td>10</td><td></td></tr><tr><td>VEGF expression</td><td></td><td></td><td>0.003</td><td></td><td></td><td>0.999</td></tr><tr><td> Negative</td><td>12</td><td>5</td><td></td><td>9</td><td>7</td><td></td></tr><tr><td> Positive</td><td>9</td><td>26</td><td></td><td>9</td><td>7</td><td></td></tr></table>
527a53e2defdf81eea993b87a8930c3b658e7fb8b5572d760f1fe9c6cb82fba0.png
complex
<table><tr><td>Accession</td><td>Hydroxycinnamic Acids</td><td>ORAC</td><td>DPPH</td><td>TRC</td><td>NO Inhibition</td></tr><tr><td colspan="6"><i>S. muricatum</i></td></tr><tr><td>37-A</td><td>5</td><td>2</td><td>4</td><td>2</td><td>1</td></tr><tr><td>El Camino</td><td>3</td><td>4</td><td>5</td><td>4</td><td>5</td></tr><tr><td>Puzol</td><td>2</td><td>3</td><td>2</td><td>5</td><td>2</td></tr><tr><td>Valencia</td><td>1</td><td>5</td><td>3</td><td>3</td><td>4</td></tr><tr><td colspan="6"><i>S. caripense</i></td></tr><tr><td>E-7</td><td>4</td><td>1</td><td>1</td><td>1</td><td>3</td></tr></table>
495e09e702afbe3e0dfb4b116e1bd2b9f4e03b612524abe3bb853d84a9867030.png
complex
<table><tr><td rowspan="3">Region</td><td colspan="2">Diseased animals</td><td colspan="2">Apparently healthy animals</td><td colspan="2">Total</td></tr><tr><td>Number of isolates as detected from 16SrRNA</td><td>Positive for <i>SeM</i> gene</td><td>Number of isolates as detected from 16SrRNA</td><td>Positive for <i>SeM</i> gene</td><td>Number of isolates as detected from 16SrRNA</td><td>Positive for <i>SeM</i> gene</td></tr><tr><td>R.S. Pura</td><td>4</td><td>0</td><td>1</td><td>0</td><td>5</td><td>0</td></tr><tr><td>Katra</td><td>12</td><td>2</td><td>3</td><td>0</td><td>15</td><td>2</td></tr><tr><td>Total</td><td>16</td><td>2</td><td>4</td><td>0</td><td>20</td><td>2</td></tr></table>
bc94cfb3fd4f232d6183cda1f276ce61d848770e61e643d28abd232445df8c8f.png
complex
<table><tr><td></td><td>Brain region</td><td>Hemisphere</td><td>NVtxs</td><td>Size (mm<sup>2</sup>)</td><td>X</td><td>Y</td><td>Z</td><td>Max</td><td>CWP</td></tr><tr><td colspan="10"><i>Group comparisons</i></td></tr><tr><td>HC &gt; CD</td><td>Superior temporal gyrus</td><td>R</td><td>338</td><td>154.4</td><td>64</td><td>&#8722;37</td><td>13</td><td>3.5</td><td>0.001</td></tr><tr><td>CD &gt; HC</td><td>None significant at CWP &#8804; 0.001</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CO-CD &gt; AO-CD and vice-versa</td><td>None at CWP &#8804; 0.001</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><i>Correlation with CU traits in the CD group</i></td></tr><tr><td>Negative correlation</td><td>Lingual gyrus</td><td>L</td><td>399</td><td>168.9</td><td>&#8722;22</td><td>&#8722;54</td><td>&#8722;2</td><td>4.3</td><td>0.0007</td></tr><tr><td>Positive correlation</td><td>None at CWP &#8804; 0.001</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><i>Correlation with lifetime CD symptoms in the CD group</i></td></tr><tr><td>Negative correlation</td><td>Inferior parietal lobule</td><td>R</td><td>344</td><td>184.6</td><td>45</td><td>&#8722;64</td><td>32</td><td>3.5</td><td>0.0002</td></tr><tr><td>Positive correlation</td><td>Inferior frontal gyrus (pars opercularis)</td><td>R</td><td>297</td><td>169.5</td><td>47</td><td>25</td><td>20</td><td>3.2</td><td>0.0007</td></tr></table>
79951c92d93fe30330109e0f83dd43ca9294fccade439d1ea6acaa1406a77a35.png
simple
<table><tr><td>NHI Code</td><td>Treatment</td><td>(n = 13,261)</td><td>%</td></tr><tr><td>45010C</td><td>Supportive individual psychotherapy</td><td>2117</td><td>16.0</td></tr><tr><td>45087C</td><td>Re-educative individual psychotherapy-adult</td><td>1578</td><td>11.9</td></tr><tr><td>45088C</td><td>Re-educative individual psychotherapy: 6&#8211;15 years old</td><td>127</td><td>1.0</td></tr><tr><td>45100C</td><td>Behavior modification assessment</td><td>49</td><td>0.4</td></tr><tr><td>45013C</td><td>Intensive individual psychotherapy-adult</td><td>34</td><td>0.3</td></tr><tr><td>45016C</td><td>Supportive group psychotherapy</td><td>33</td><td>0.2</td></tr><tr><td>45094C</td><td>Re-educative group psychotherapy</td><td>24</td><td>0.2</td></tr><tr><td>45022C</td><td>Activity therapy (day)</td><td>24</td><td>0.2</td></tr><tr><td>45043C</td><td>Biofeedback therapy</td><td>14</td><td>0.1</td></tr><tr><td>45089C</td><td>Re-educative individual psychotherapy-under 6 years old</td><td>12</td><td>0.1</td></tr><tr><td>45095C</td><td>Special Occupational therapy</td><td>10</td><td>0.1</td></tr><tr><td>45090C</td><td>Intensive individual psychotherapy: 6&#8211;15 years old</td><td>7</td><td>0.1</td></tr></table>
d5996ba9872141421ca0a9d147d900e81884028e0e315488486600f4c6de7e6b.png
simple
<table><tr><td></td><td>All patients</td><td>L5/S1 herniations with high iliac crest</td><td>Herniations with scoliosis</td><td>Herniation with calcification</td></tr><tr><td>No. of patients in category</td><td>209</td><td>29</td><td>25</td><td>31</td></tr><tr><td>Excellent or good <i>n</i> (%)</td><td>200 (95.7)</td><td>29 (100)</td><td>25 (100)</td><td>30 (96.8)</td></tr><tr><td>Fair <i>n</i> (%)</td><td>6 (2.9)</td><td>0 (0)</td><td>0 (0)</td><td>1 (3.2)</td></tr><tr><td>Poor <i>n</i> (%)</td><td>3 (1.4)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr></table>
f7cf35b15f05e8043bc45a01c19cb44e979746c17e31d2ba029d27cba0dcfb7f.png
simple
<table><tr><td></td><td>RL</td><td>AP</td><td>SI</td><td>Net</td></tr><tr><td>Range</td><td>0-0.85</td><td>0-1.83</td><td>0-1.96</td><td>0.10-2.01</td></tr><tr><td>Average (Right shoulder)</td><td>0.22</td><td>0.36</td><td>0.35</td><td>0.55</td></tr><tr><td>Average (Left shoulder)</td><td>0.26</td><td>0.48</td><td>0.27</td><td>0.60</td></tr><tr><td>Average net</td><td></td><td></td><td></td><td>0.58</td></tr></table>
f958b46f8a326e511cda2f099cf8f878492efd28e18a97d71c44e514f8b57a9e.png
simple
<table><tr><td>F508del</td><td>Sex</td><td>Male</td><td>Female</td><td>Chi-square</td><td>p-value</td></tr><tr><td>-/-</td><td>G/G</td><td>8 (53.3%)</td><td>7 (46.7%)</td><td>0.257</td><td>0.613</td></tr><tr><td> </td><td>G/T and T/T</td><td>15 (45.5%)</td><td>18 (54.5%)</td><td> </td><td> </td></tr><tr><td>F508del/-</td><td>G/G</td><td>13 (48.1%)</td><td>14 (51.9%)</td><td>0.931</td><td>0.335</td></tr><tr><td> </td><td>G/T and T/T</td><td>20 (60.6%)</td><td>13 (39.4%)</td><td> </td><td> </td></tr><tr><td>F508del/F508del</td><td>G/G</td><td>5 (41.7%)</td><td>7 (58.3%)</td><td>0.018</td><td>0.893</td></tr><tr><td> </td><td>G/T and T/T</td><td>11 (44%)</td><td>14 (54%)</td><td> </td><td> </td></tr><tr><td>F508del</td><td>Diabetes</td><td>No</td><td>Yes</td><td> </td><td> </td></tr><tr><td>-/-</td><td>G/G</td><td>12 (80%)</td><td>3 (20%)</td><td>0.01</td><td>0.919</td></tr><tr><td> </td><td>G/T and T/T</td><td>26 (81.3%)</td><td>6 (18.8%)</td><td> </td><td> </td></tr><tr><td>F508del/-</td><td>G/G</td><td>19 (70.4%)</td><td>8 (29.6%)</td><td>2.652</td><td>0.103</td></tr><tr><td> </td><td>G/T and T/T</td><td>28 (87.5%)</td><td>4 (12.5%)</td><td> </td><td> </td></tr><tr><td>F508del/F508del</td><td>G/G</td><td>8 (66.7%)</td><td>4 (33.3%)</td><td>1.437</td><td>0.231</td></tr><tr><td> </td><td>G/T and T/T</td><td>21 (84%)</td><td>4 (16%)</td><td> </td><td> </td></tr><tr><td>F508del</td><td>Meconium ileus</td><td>No</td><td>Yes</td><td> </td><td> </td></tr><tr><td>-/-</td><td>G/G</td><td>15 (100%)</td><td>-</td><td>1.455</td><td>0.228</td></tr><tr><td> </td><td>G/T and T/T</td><td>30 (90.9%)</td><td>3 (9.1%)</td><td> </td><td> </td></tr><tr><td>F508del/-</td><td>G/G</td><td>22 (81.5%)</td><td>5 (18.5%)</td><td>0.067</td><td>0.795</td></tr><tr><td> </td><td>G/T and T/T</td><td>26 (78.8%)</td><td>7 (21.2%)</td><td> </td><td> </td></tr><tr><td>F508del/F508del</td><td>G/G</td><td>10 (83.3%)</td><td>2 (16.7%)</td><td>0.566</td><td>0.452</td></tr><tr><td> </td><td>G/T and T/T</td><td>18 (72%)</td><td>7 (28%)</td><td> </td><td> </td></tr><tr><td>F508del</td><td>Age</td><td>&#8804; 154 months</td><td>&gt; 154 months</td><td> </td><td> </td></tr><tr><td>-/-</td><td>G/G</td><td>4 (26.7%)</td><td>11 (73.3%)</td><td>0.032</td><td>0.857</td></tr><tr><td> </td><td>G/T and T/T</td><td>8 (24.2%)</td><td>25 (75.8%)</td><td> </td><td> </td></tr><tr><td>F508del/-</td><td>G/G</td><td>15 (55.6%)</td><td>12 (44.4%)</td><td>0.297</td><td>0.586</td></tr><tr><td> </td><td>G/T and T/T</td><td>16 (48.5%)</td><td>17 (51.5%)</td><td> </td><td> </td></tr><tr><td>F508del/F508del</td><td>G/G</td><td>9 (75%)</td><td>3 (25%)</td><td>1.009</td><td>0.315</td></tr><tr><td> </td><td>G/T and T/T</td><td>22 (88%)</td><td>3 (12%)</td><td> </td><td> </td></tr></table>
442b92b67e2c74cfa7fe57b142ba87a4330d6ad8c08a5db6e2e5bb4dda9fdc06.png
simple
<table><tr><td>Study reference</td><td>Study design</td><td>Reported inclusion/exclusion criteria</td><td>Reported double blind</td><td>Reported clinically-labeled products</td><td>Reported sample power estimation</td><td>Reported adverse events</td><td>Reported study completion ratio</td><td>Overall quality factor scores</td></tr><tr><td>Study 2 from Lloyd et al. 1999 [8]</td><td>Randomized Parallel group</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>1</td><td>5/6</td></tr><tr><td>Study 1 from Lloyd et al. 1999 [8]</td><td>Randomized Parallel group</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>1</td><td>4/6</td></tr><tr><td>Study 1 from Ostrom et al. 2002 [7]</td><td>Randomized Crossover</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>1</td><td>3/6</td></tr><tr><td>Study 2 from Ostrom et al. 2002 [7]</td><td>Randomized Crossover</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>1</td><td>4/6</td></tr><tr><td>Borschel et al. 2012 [11]</td><td>Randomized Parallel group</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>6/6</td></tr><tr><td>Borschel et al. 2014 [10]</td><td>Randomized Parallel group</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>6/6</td></tr><tr><td>Leite et al. 2013 [9]</td><td>Randomized Crossover <sup>1</sup></td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>1</td><td>5/6</td></tr><tr><td>Nelson et al. 1996 [6]</td><td>Randomized Crossover</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>1</td><td>3/6</td></tr><tr><td>Nelson et al. 1998 [5]</td><td>Randomized Crossover</td><td>0</td><td>1</td><td>1</td><td>0</td><td>1</td><td>1</td><td>4/6</td></tr></table>
06df98beaa79f3380b3c6ea699d544542d7765cd2b656287f141207ccefa71f4.png
complex
<table><tr><td rowspan="2"></td><td>With tumor thrombus</td><td rowspan="2"><i>P</i></td><td>Without tumor thrombus</td><td rowspan="2"><i>P</i></td></tr><tr><td>OR(%95 CI)</td><td>OR (%95 CI)</td></tr><tr><td>AFP, ng/mL (&gt; 20 vs. &#8804; 20)</td><td>1.1 (0.9, 1.3)</td><td>0.479</td><td>1.1 (0.7, 1.7)</td><td>0.746</td></tr><tr><td>Tumor size, cm (&gt; 5 vs. &#8804; 5)</td><td>1.7 (1.4, 2.0)</td><td>&lt;0.001*</td><td>0.9 (0.6, 1.5)</td><td>0.717</td></tr><tr><td>Tumor number (&gt; 3 vs. &#8804; 3)</td><td>1.0 (0.8, 1.3)</td><td>0.992</td><td>1.3 (0.8, 2.1)</td><td>0.328</td></tr><tr><td>Tumor location (more than one vs. one lobe)</td><td>1.0 (0.8, 1.2)</td><td>0.673</td><td>2.1 (1.5, 3.0)</td><td>&lt;0.001*</td></tr><tr><td>Tumor capsule (absent vs. present)</td><td>1.1 (0.9, 1.3)</td><td>0.261</td><td>1.0 (0.7, 1.5)</td><td>0.928</td></tr><tr><td>Tumor differentiate (III-IV vs. I-II)</td><td>1.2 (1.0, 1.4)</td><td>0.071</td><td>1.1 (0.8, 1.6)</td><td>0.610</td></tr></table>
9c8962529187e349e7994f2b87f86b0b41eb8255616ab1cd14eb7ed9c8cbfd0a.png
simple
<table><tr><td>No</td><td>A</td><td>B</td><td>C</td><td>D</td><td>extract weight(%)y1</td><td>TTC(%)y2</td><td>score z</td></tr><tr><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>56.76</td><td>22.54</td><td>73.79</td></tr><tr><td>2</td><td>1</td><td>2</td><td>2</td><td>2</td><td>69.10</td><td>24.97</td><td>85.14</td></tr><tr><td>3</td><td>1</td><td>3</td><td>3</td><td>3</td><td>73.18</td><td>30.92</td><td>98.65</td></tr><tr><td>4</td><td>2</td><td>1</td><td>2</td><td>3</td><td>72.14</td><td>31.63</td><td>99.44</td></tr><tr><td>5</td><td>2</td><td>2</td><td>3</td><td>1</td><td>34.94</td><td>26.04</td><td>68.46</td></tr><tr><td>6</td><td>2</td><td>3</td><td>1</td><td>2</td><td>64.81</td><td>24.73</td><td>82.34</td></tr><tr><td>7</td><td>3</td><td>1</td><td>3</td><td>2</td><td>62.08</td><td>30.09</td><td>91.09</td></tr><tr><td>8</td><td>3</td><td>2</td><td>1</td><td>3</td><td>65.58</td><td>28.54</td><td>89.99</td></tr><tr><td>9</td><td>3</td><td>3</td><td>2</td><td>1</td><td>52.24</td><td>24.25</td><td>74.56</td></tr><tr><td>K1</td><td>257.58</td><td>264.32</td><td>246.12</td><td>216.81</td><td></td><td></td><td></td></tr><tr><td>K2</td><td>250.24</td><td>243.59</td><td>259.14</td><td>258.57</td><td></td><td></td><td></td></tr><tr><td>K3</td><td>255.64</td><td>255.55</td><td>258.20</td><td>288.08</td><td></td><td></td><td></td></tr><tr><td>k1</td><td>85.86</td><td>88.11</td><td>82.04</td><td>72.27</td><td></td><td></td><td></td></tr><tr><td>k2</td><td>83.41</td><td>81.20</td><td>86.38</td><td>86.19</td><td></td><td></td><td></td></tr><tr><td>k3</td><td>85.21</td><td>85.18</td><td>86.07</td><td>96.03</td><td></td><td></td><td></td></tr><tr><td>R</td><td>2.45</td><td>6.91</td><td>4,34</td><td>23.76</td><td></td><td></td><td></td></tr></table>
7156f2cbac62cc874d6f614518f24f61d47efb9f21ced9ef6b4e2cf2ba032c8a.png
simple
<table><tr><td> </td><td><i>WT</i></td><td><i>+/-</i></td><td><i>-/-</i></td></tr><tr><td>Early-stage seizure</td><td>0</td><td>+</td><td>++</td></tr><tr><td>Myoclonic jerks</td><td>0</td><td>+*</td><td>0</td></tr><tr><td>Clonic seizure</td><td>0</td><td>&#8722;*</td><td>&#8722;&#8722;</td></tr><tr><td>Repetitive jumping</td><td>0</td><td>(+)</td><td>++</td></tr><tr><td>Social preference</td><td>0</td><td>(+)</td><td>++</td></tr><tr><td>Ultrasonic vocalization</td><td>0</td><td>(&#8722;)*</td><td>&#8722;&#8722;</td></tr><tr><td>Nest building</td><td>0</td><td>&#8722;</td><td>&#8722;&#8722;</td></tr><tr><td>Acoustic startle response</td><td>0</td><td>&#8722;</td><td>&#8722;&#8722;</td></tr><tr><td>Prepulse inhibition</td><td>0</td><td>(&#8722;)</td><td>&#8722;&#8722;</td></tr><tr><td>Cue test (fear conditioning)</td><td>0</td><td>(&#8722;)</td><td>&#8722;&#8722;</td></tr></table>
4722c45252e375db01143e74ac5724bb201ab176c933675e694358bcd6765b4e.png
simple
<table><tr><td>Up-regulated miRNAs</td><td>Fold-change</td><td><i>P</i></td></tr><tr><td>miR-7</td><td>10.91</td><td>0.005</td></tr><tr><td>miR-196b</td><td>7.67</td><td>0.030</td></tr><tr><td>miR-424</td><td>6.75</td><td>0.008</td></tr><tr><td>miR-18b</td><td>6.67</td><td>0.002</td></tr><tr><td>miR-223</td><td>6.31</td><td>0.003</td></tr><tr><td>miR-130b</td><td>5.18</td><td>0.005</td></tr></table>
f49227b2874551f92bac8eaed2ceebf875f16ab33ecadffa9b84e9ba23b77a8e.png
complex
<table><tr><td>Statement</td><td>Depression Vignette</td><td>Depression/Suicidal Vignette</td><td>Early Schizophrenia Vignette</td><td>Chronic Schizophrenia Vignette</td></tr><tr><td colspan="5">Person could snap out of the problem</td></tr><tr><td>Australian</td><td>24.7 (21.7%&#8211;27.9%)</td><td>22.7 (19.9%&#8211;25.7%)</td><td>18.3 (15.6%&#8211;21.3%)</td><td>17.9 (15.0%&#8211;21.2%)</td></tr><tr><td>Japanese</td><td>47.2 <sup>* d </sup>(42.8%&#8211;51.6%)</td><td>49.4 <sup>* d </sup>(45.0%&#8211;53.8%)</td><td>41.2* (36.9%&#8211;45.5%)</td><td>36.4 <sup>* a,b </sup>(32.2%&#8211;40.6%)</td></tr><tr><td colspan="5">Problem is a sign of personal weakness</td></tr><tr><td>Australian</td><td>13.4 (11.0%&#8211;16.2%)</td><td>16.9 (14.4%&#8211;19.6%)</td><td>19.3 (16.6%&#8211;22.4%)</td><td>14.0 (11.7%&#8211;16.7%)</td></tr><tr><td>Japanese</td><td>45.4* (41.0%&#8211;49.8%)</td><td>45.0* (40.6%&#8211;49.4%)</td><td>46.6* (42.2%&#8211;51.0%)</td><td>46.0* (41.6%&#8211;50.4%)</td></tr><tr><td colspan="5">Problem is not a real medical illness</td></tr><tr><td>Australian</td><td>14.6 (12.3%&#8211;17.1%)</td><td>15.2 (13.0%&#8211;17.8%)</td><td>14.9 (12.7%&#8211;17.4%)</td><td>13.9 (11.7%&#8211;16.6%)</td></tr><tr><td>Japanese</td><td>40.2* (35.9%&#8211;44.5%)</td><td>38.4* (34.1%&#8211;42.7%)</td><td>31.4* (27.3%&#8211;35.5%)</td><td>35.8* (31.6%&#8211;40.0%)</td></tr><tr><td colspan="5">People with this problem are dangerous</td></tr><tr><td>Australian</td><td>11.9 <sup>c,d </sup>(9.8%&#8211;14.3%)</td><td>18.3 <sup>c </sup>(15.7%&#8211;21.2%)</td><td>24.9 <sup>a,b </sup>(22.2%&#8211;27.8%)</td><td>22.5 <sup>a </sup>(19.6%&#8211;25.7%)</td></tr><tr><td>Japanese</td><td>14.6 <sup>d </sup>(11.5%&#8211;17.7%)</td><td>16.0 <sup>d </sup>(12.8%&#8211;19.2%)</td><td>20.4 <sup>d </sup>(16.9%&#8211;23.9%)</td><td>37.6 <sup>* a,b,c </sup>(33.3%&#8211;41.9%)</td></tr><tr><td colspan="5">Avoid people with this problem</td></tr><tr><td>Australian</td><td>6.9 (5.3%&#8211;9.0%)</td><td>4.7 (3.5%&#8211;6.4%)</td><td>4.9 (3.6%&#8211;6.6%)</td><td>5.2 (3.9%&#8211;7.0%)</td></tr><tr><td>Japanese</td><td>7.8 <sup>d </sup>(5.4%&#8211;10.2%)</td><td>5.8 <sup>c,d </sup>(3.7%&#8211;7.9%)</td><td>11.8 <sup>*,b </sup>(9.0%&#8211;14.6%)</td><td>17.8 <sup>* a,b </sup>(14.4%&#8211;21.2%)</td></tr><tr><td colspan="5">People with this problem are unpredictable</td></tr><tr><td>Australian</td><td>42.2 <sup>c,d </sup>(38.8%&#8211;45.6%)</td><td>51.1 <sup>c,d </sup>(47.6%&#8211;54.5%)</td><td>67.1 <sup>a,b </sup>(63.9%&#8211;70.1%)</td><td>67.5 <sup>a,b </sup>(64.1%&#8211;70.7%)</td></tr><tr><td>Japanese</td><td>18.6 <sup>* c,d </sup>(15.2%&#8211;22.0%)</td><td>20.0 <sup>* c,d </sup>(16.5%&#8211;23.5%)</td><td>31.0 <sup>* a,b,d </sup>(26.9%&#8211;35.1%)</td><td>45.6 <sup>* a,b,c </sup>(41.2%&#8211;50.0%)</td></tr><tr><td colspan="5">If I had this problem I wouldn't tell anyone</td></tr><tr><td>Australian</td><td>17.0 <sup>c,d </sup>(14.5%&#8211;19.9%)</td><td>21.5 <sup>d </sup>(18.8%&#8211;24.3%)</td><td>26.7 <sup>a </sup>(23.8%&#8211;29.8%)</td><td>31.1 <sup>a,b </sup>(28.1%&#8211;34.3%)</td></tr><tr><td>Japanese</td><td>26.8 <sup>* d </sup>(22.9%&#8211;30.7%)</td><td>24.8 <sup>c,d </sup>(21.0%&#8211;28.6%)</td><td>35.0 <sup>b </sup>(30.8%&#8211;39.2%)</td><td>37.2 <sup>a,b </sup>(32.9%&#8211;41.5%)</td></tr><tr><td colspan="5">I would not employ someone with this problem</td></tr><tr><td>Australian</td><td>21.6 <sup>d </sup>(19.2%&#8211;24.3%)</td><td>22.5 <sup>d </sup>(19.8%&#8211;25.4%)</td><td>24.8 (22.0%&#8211;27.9%)</td><td>32.4 <sup>a,b </sup>(29.2%&#8211;35.8%)</td></tr><tr><td>Japanese</td><td>38.6 <sup>* d </sup>(34.3%&#8211;42.9%)</td><td>38.6 <sup>* d </sup>(34.3%&#8211;42.9%)</td><td>47.6 <sup>* d </sup>(43.2%&#8211;52.0%)</td><td>61.2 <sup>* a,b,c </sup>(56.9%&#8211;65.5%)</td></tr><tr><td colspan="5">I would not vote for a politician with this problem</td></tr><tr><td>Australian</td><td>30.1 <sup>d </sup>(26.9%&#8211;33.4%)</td><td>32.5 <sup>d </sup>(29.4%&#8211;35.8%)</td><td>35.3 <sup>d </sup>(32.2%&#8211;38.5%)</td><td>45.7 <sup>a,b,c </sup>(42.5%&#8211;49.0%)</td></tr><tr><td>Japanese</td><td>58.0 <sup>* d </sup>(53.7%&#8211;62.3%)</td><td>53.8 <sup>* d </sup>(49.4%&#8211;58.2%)</td><td>58.0 <sup>* d </sup>(53.7%&#8211;62.3%)</td><td>73.8 <sup>* a,b,c </sup>(69.9%&#8211;77.7%)</td></tr></table>
7b42396457df0300486da1691278c17cd6040b06b61540e1ba3dbf6df8fc78d9.png
complex
<table><tr><td></td><td colspan="2">OR (95% CI)</td></tr><tr><td>Pregnancy outcome (<i>n</i>)</td><td>Unadjusted</td><td>Adjusteda</td></tr><tr><td colspan="3">Term [&#8805; 37 weeks (923)]</td></tr><tr><td>All preterm [&lt; 37 weeks (101)]</td><td>1.1 (0.6&#8211;2.2)</td><td>1.55 (0.7&#8211;2.9)</td></tr><tr><td>Moderately preterm [35&#8211;36 weeks (57)]</td><td>0.3 (0.1&#8211;1.4)</td><td>0.4 (0.1&#8211;1.9)</td></tr><tr><td>Very preterm [&lt; 35 weeks (44)]</td><td>2.4 (1.1&#8211;5.1)</td><td>3.0 (1.3&#8211;6.7)</td></tr></table>
776dd136dac17669ad393c92072448a01f9d6bf4942a03b643093d4ba21e731f.png
simple
<table><tr><td>Targeted agent</td><td>Chemotherapy</td><td>N</td><td>RR</td><td>PFS (months)</td><td>OS (months)</td><td>Reference</td></tr><tr><td>Cetuximab</td><td>Irinotecan and FU</td><td>49</td><td>42%</td><td>8.6</td><td>16.6</td><td>Kanzler et al. [11]</td></tr><tr><td>Bevacizumab</td><td>Docetaxel, FU and cisplatin</td><td>44</td><td>67%</td><td>12</td><td>16.2</td><td>Kelsen et al. [12]</td></tr><tr><td>Cetuximab</td><td>Irinotecan and oxaliplatin</td><td>51</td><td>60%</td><td>6</td><td>9.5</td><td>Woell et al. [13]</td></tr></table>
699de5b5f7816bc5c7a164cfc57c66d4e5fe8327e7e69af6d7ee32b898775d82.png
simple
<table><tr><td>ID</td><td>Protein change</td><td><sup>a</sup>Nucleotide change</td><td>Mutation type</td><td><sup>d</sup>PolyPhen-2</td><td><sup>e</sup>SIFT</td><td>Predicted function</td><td>Mutant ratio</td></tr><tr><td>777T</td><td>Y249X</td><td>747T&gt;A</td><td></td><td>nonsense</td><td></td><td>Loss of function</td><td>0.91</td></tr><tr><td>869T</td><td>G869E</td><td>2606G&gt;A</td><td>missense</td><td>damaging</td><td>damaging</td><td>Damaging</td><td>0.51</td></tr><tr><td>163T</td><td>C911F</td><td>2732G&gt;T</td><td>missense</td><td>damaging</td><td>tolerated</td><td>Uncertain</td><td>0.49</td></tr><tr><td>324T</td><td>S947C</td><td>2840C&gt;G</td><td>missense</td><td>benign</td><td>damaging</td><td>Uncertain</td><td>0.61</td></tr><tr><td>970T</td><td>P226RfsX4</td><td>677_693del17</td><td>frameshift</td><td></td><td></td><td>Loss of function</td><td>0.19</td></tr><tr><td>981T</td><td>P226RfsX4</td><td>677_693del17</td><td>frameshift</td><td></td><td></td><td>Loss of function</td><td>0.23</td></tr><tr><td>1278T</td><td>F1250del</td><td>3747_3749del</td><td>in-frame del</td><td></td><td></td><td>Uncertain</td><td>0.14</td></tr><tr><td><sup>b</sup>ACCMESO1</td><td>V132EfsX3</td><td>395_399del5</td><td>frameshift</td><td></td><td></td><td>Loss of function</td><td></td></tr><tr><td><sup>c</sup>NYU695</td><td>K674SfsX73</td><td>2020delA</td><td>frameshift</td><td></td><td></td><td>Loss of function</td><td></td></tr></table>
db9027bf58d278ad8dd431bc1c655b901be68339dde06d822d6e0cdc0097581c.png
complex
<table><tr><td rowspan="2"></td><td rowspan="2">Johnsen Score</td><td rowspan="2">Parameters</td><td rowspan="2">Area Under the Curve</td><td rowspan="2">Std. Error</td><td rowspan="2">Asymptotic Sig.</td><td colspan="2">Asymptomic 95% Confidence Interval</td></tr><tr><td>Lower Bound</td><td>Upper Bound</td></tr><tr><td rowspan="7">Left Testis</td><td rowspan="2">&#8805;8</td><td>Testis Volume</td><td>0.796</td><td>0.034</td><td>0.000</td><td>0.729</td><td>0.863</td></tr><tr><td>TT</td><td>0.544</td><td>0.043</td><td>0.308</td><td>0.459</td><td>0.629</td></tr><tr><td rowspan="5">&#8804;7</td><td>age</td><td>0.546</td><td>0.043</td><td>0.290</td><td>0.461</td><td>0.631</td></tr><tr><td>PRL</td><td>0.587</td><td>0.043</td><td>0.044</td><td>0.503</td><td>0.671</td></tr><tr><td>FSH</td><td>0.627</td><td>0.042</td><td>0.003</td><td>0.545</td><td>0.710</td></tr><tr><td>LH</td><td>0.561</td><td>0.043</td><td>0.156</td><td>0.477</td><td>0.645</td></tr><tr><td>E2</td><td>0.688</td><td>0.042</td><td>0.000</td><td>0.605</td><td>0.771</td></tr><tr><td rowspan="7">Right Testis</td><td rowspan="4">&#8805;8</td><td>Testis Volume</td><td>0.791</td><td>0.035</td><td>0.000</td><td>0.721</td><td>0.860</td></tr><tr><td>age</td><td>0.556</td><td>0.043</td><td>0.193</td><td>0.472</td><td>0.641</td></tr><tr><td>LH</td><td>0.552</td><td>0.043</td><td>0.231</td><td>0.467</td><td>0.636</td></tr><tr><td>TT</td><td>0.574</td><td>0.043</td><td>0.085</td><td>0.491</td><td>0.658</td></tr><tr><td rowspan="3">&#8804;7</td><td>PRL</td><td>0.547</td><td>0.043</td><td>0.274</td><td>0.463</td><td>0.632</td></tr><tr><td>FSH</td><td>0.537</td><td>0.044</td><td>0.395</td><td>0.451</td><td>0.623</td></tr><tr><td>E2</td><td>0.716</td><td>0.039</td><td>0.000</td><td>0.641</td><td>0.792</td></tr></table>
31b57836600699f39bcabda53f8dbd4308c4a580c2f1443f84e6c02a8303a096.png
simple
<table><tr><td>No.</td><td>Age</td><td>Gender</td><td>BSA (m<sup>2</sup>)</td><td>MSKCC risk</td><td>Metastatic sites</td><td>Prior therapy</td></tr><tr><td>1</td><td>70</td><td>Female</td><td>1.298</td><td>Intermediate</td><td>Lung, Lymph nodes</td><td>None</td></tr><tr><td>2</td><td>58</td><td>Female</td><td>1.446</td><td>Favorable</td><td>Abdominal wall, Lung, liver</td><td>None</td></tr><tr><td>3</td><td>56</td><td>Male</td><td>1.929</td><td>Intermediate</td><td>Lung</td><td>Interferon</td></tr><tr><td>4</td><td>79</td><td>Male</td><td>1.710</td><td>Favorable</td><td>Pancreas, Contralateral kidney</td><td>None</td></tr><tr><td>5</td><td>62</td><td>Male</td><td>1.893</td><td>Favorable</td><td>Pleura</td><td>None</td></tr><tr><td>6</td><td>64</td><td>Male</td><td>1.659</td><td>Intermediate</td><td>Lung</td><td>None</td></tr></table>
0e0d453764ad5a7ee457efb2edcf6364da79d706fc79282318356deaa44dcd5b.png
complex
<table><tr><td>Dependent variable: 2009 performance score</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td>(1)</td><td>(2)</td><td>(3)</td><td>(4)</td><td>(5)</td></tr><tr><td>Private</td><td>&#8722;6.212</td><td>&#8722;7.030</td><td>&#8722;7.026</td><td>&#8722;5.548</td><td>&#8722;5.311</td></tr><tr><td> </td><td>(3.651)*</td><td>(3.615)*</td><td>(3.506)**</td><td>(3.556)</td><td>(3.505)</td></tr><tr><td>Weifang</td><td>5.578</td><td>6.234</td><td>6.313</td><td>6.368</td><td>6.994</td></tr><tr><td> </td><td>(2.273)**</td><td>(2.137)***</td><td>(1.999)***</td><td>(2.351)***</td><td>(2.223)***</td></tr><tr><td>Private*Weifang</td><td>7.480</td><td>7.585</td><td>7.273</td><td>6.789</td><td>6.035</td></tr><tr><td> </td><td>(3.940)*</td><td>(3.885)*</td><td>(3.709)*</td><td>(3.874)*</td><td>(3.809)</td></tr><tr><td>Clinic space (m<sup>2</sup>)</td><td>0.007</td><td>&#8722;0.000</td><td>0.000</td><td> </td><td> </td></tr><tr><td> </td><td>(0.004)*</td><td>(0.001)</td><td>(0.001)</td><td> </td><td> </td></tr><tr><td>Value of fixed assets</td><td>&#8722;0.023</td><td> </td><td> </td><td>&#8722;0.007</td><td>&#8722;0.007</td></tr><tr><td> </td><td>(0.014)</td><td> </td><td> </td><td>(0.008)</td><td>(0.007)</td></tr><tr><td>Number of beds</td><td>0.296</td><td>0.330</td><td>0.352</td><td>0.248</td><td>0.277</td></tr><tr><td> </td><td>(0.280)</td><td>(0.267)</td><td>(0.249)</td><td>(0.268)</td><td>(0.264)</td></tr><tr><td>Number of staff members</td><td>0.206</td><td>0.147</td><td>0.120</td><td>0.362</td><td>0.323</td></tr><tr><td> </td><td>(0.194)</td><td>(0.168)</td><td>(0.158)</td><td>(0.205)*</td><td>(0.179)*</td></tr><tr><td rowspan="2">Dummy for medical insurance appointed health stations</td><td>&#8722;0.407</td><td>&#8722;0.852</td><td> </td><td>&#8722;1.135</td><td> </td></tr><tr><td>(3.047)</td><td>(2.932)</td><td> </td><td>(3.059)</td><td> </td></tr><tr><td rowspan="2">Dummy for implementing the policy of separating prescribing from dispensing</td><td>1.939</td><td>&#8722;0.754</td><td> </td><td>0.604</td><td> </td></tr><tr><td>(2.608)</td><td>(2.229)</td><td> </td><td>(2.226)</td><td> </td></tr><tr><td>Constant</td><td>70.534</td><td>72.637</td><td>72.083</td><td>70.907</td><td>70.283</td></tr><tr><td> </td><td>(3.793)***</td><td>(3.755)***</td><td>(2.693)***</td><td>(3.770)***</td><td>(2.910)***</td></tr><tr><td>Observations</td><td>90</td><td>100</td><td>106</td><td>92</td><td>94</td></tr><tr><td>Adjusted R-squared</td><td>0.16</td><td>0.18</td><td>0.21</td><td>0.15</td><td>0.18</td></tr></table>
1a74357a872ceb0dcdfab8ce96e23c24cb8ce63773b6154e048c1d97e7ff0664.png
simple
<table><tr><td>Sequence</td><td>Faster adaptation for the lens of period 1 (immediate or few hours)</td><td>No difference</td><td>Faster adaptation for the lens of period 2 (immediate or few hours)</td><td>TOTAL</td></tr><tr><td></td><td>N</td><td>N</td><td>N</td><td>N</td></tr><tr><td>New-generation lens then older-generation lens</td><td>14</td><td>35</td><td>12</td><td>61</td></tr><tr><td>Older-generation lens then new-generation lens</td><td>5</td><td>39</td><td>19</td><td>63</td></tr><tr><td>TOTAL</td><td>19</td><td>74</td><td>31</td><td>124</td></tr></table>
6adcf219b36f470e2842b66e8dec55166427890746811fc683c6f96202e744c0.png
simple
<table><tr><td>Outcomes</td><td>Lifestyle intervention group n = 27<sup>a</sup></td><td>Close follow-up group n = 27</td><td>p value<sup>b</sup></td></tr><tr><td>Total weight gain (kg)</td><td>11.4 &#177; 6.0</td><td>13.9 &#177; 5.1</td><td>NS</td></tr><tr><td>Weight at the end of pregnancy ( kg)</td><td>88.6 &#177; 14.4</td><td>84.1 &#177; 11.3</td><td>NS</td></tr><tr><td>Fasting glucose (mmol/l)</td><td>4.6 &#177; 0.4</td><td>4.4 &#177; 0.3</td><td>NS</td></tr><tr><td>OGTT 1-hour glucose (mmol/l)</td><td>6.9 &#177; 1.7</td><td>6.9 &#177; 1.7</td><td>NS</td></tr><tr><td>OGTT 2-hour glucose (mmol/l)</td><td>6.1 &#177; 1.4</td><td>6.0 &#177; 1.2</td><td>NS</td></tr><tr><td>Area under the curve (mmol/l/2 h)</td><td>12.3 &#177; 2.4</td><td>12.1 &#177; 2.2</td><td>NS</td></tr><tr><td>Gestational diabetes</td><td>3 (11.1)</td><td>1 (3.7)</td><td>NS</td></tr><tr><td>Insulin therapy</td><td>0</td><td>0</td><td>NS</td></tr></table>
f1417f141fdf08cd0db6ada419c8018ebd70d33db5ace503f4a737fa79788ee7.png
complex
<table><tr><td></td><td>Obese non-diabetic(<i>n</i> = 138)</td><td>Obese diabetic(<i>n</i> = 92)</td><td><i>p</i></td></tr><tr><td colspan="4">Physical and clinical characteristics</td></tr><tr><td>Age (years)</td><td>45.76 &#177; 9.91</td><td>48.28 &#177; 8.17</td><td>0.16</td></tr><tr><td>Gender (M/F)</td><td>71/67</td><td>49/43</td><td>0.44</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>33.82 &#177; 3.47</td><td>33.55 &#177; 2.94</td><td>0.59</td></tr><tr><td>PBF (%)</td><td>38.20 &#177; 5.35</td><td>37.02 &#177; 4.95</td><td>0.54</td></tr><tr><td>Waist (cm)</td><td>106.02 &#177; 12.00</td><td>108.88 &#177; 8.75</td><td>0.053</td></tr><tr><td>Hip (cm)</td><td>115.06 &#177; 12.64</td><td>113.96 &#177; 12.40</td><td>0.97</td></tr><tr><td>Resting HR (beats/min)</td><td>76.67 &#177; 11.01</td><td>86.01 &#177; 11.68</td><td>&lt;0.0001</td></tr><tr><td>SBP (mmHg)</td><td>120.92 &#177; 13.04</td><td>121.88 &#177; 11.92</td><td>0.64</td></tr><tr><td>DBP (mmHg)</td><td>78.13 &#177; 8.58</td><td>78.70 &#177; 6.16</td><td>0.28</td></tr><tr><td>VO2 Max (mL/kg/min)</td><td>17.57 &#177; 4.70</td><td>15.89 &#177; 4.10</td><td>0.04</td></tr><tr><td>WBC10</td><td>6.65 &#177; 1.89</td><td>7.54 &#177; 1.91</td><td>0.0003</td></tr><tr><td colspan="4">Metabolic markers</td></tr><tr><td>Cholesterol (mmol/L)</td><td>5.21 &#177; 0.89</td><td>5.05 &#177; 1.16</td><td>0.22</td></tr><tr><td>HDL (mmol/L)</td><td>1.22 &#177; 0.36</td><td>1.11 &#177; 0.33</td><td>0.027</td></tr><tr><td>LDL (mmol/L)</td><td>3.35 &#177; 0.85</td><td>3.16 &#177; 1.24</td><td>0.09</td></tr><tr><td>TG (mmol/L)</td><td>1.45 &#177; 0.95</td><td>2.10 &#177; 1.74</td><td>0.0002</td></tr><tr><td>Glucose (mmol/L)</td><td>5.43 &#177; 0.47</td><td>9.82 &#177; 3.85</td><td>&lt;0.0001</td></tr><tr><td>HbA1c (%)</td><td>5.76 &#177; 0.49</td><td>8.70 &#177; 1.93</td><td> &lt;0.0001</td></tr><tr><td>Insulin (ng/mL)</td><td>3.82 &#177; 1.94</td><td>4.22 &#177; 2.04</td><td>0.26</td></tr><tr><td>HOMA-IR</td><td>0.96 &#177; 0.55</td><td>1.60 &#177; 0.88</td><td>&lt;0.0001</td></tr><tr><td>C-peptide (g/mL)</td><td>1.88 &#177; 1.13</td><td>1.87 &#177; 1.25</td><td>0.91</td></tr><tr><td>Glucagon (ng/mL)</td><td>0.16 &#177; 0.04</td><td>0.18 &#177; 0.05</td><td>0.11</td></tr><tr><td>GIP (ng/mL)</td><td>0.76 &#177; 0.55</td><td>0.92 &#177; 0.61</td><td>0. 13</td></tr><tr><td>GLP-1 (ng/mL)</td><td>0.27 &#177; 0.05</td><td>0.29 &#177; 0.04</td><td>0.002</td></tr><tr><td>Leptin (ng/mL)</td><td>9.10 &#177; 6.25</td><td>8.66 &#177; 3.99</td><td>0.74</td></tr><tr><td colspan="4">Inflammatory markers</td></tr><tr><td>IL-1b (pg/L)</td><td>8.29 &#177; 3.28</td><td>7.82 &#177; 1.94</td><td>0.96</td></tr><tr><td>IL-6 (pg/mL)</td><td>17.30 &#177; 6.24</td><td>17.16 &#177; 4.87</td><td>0.71</td></tr><tr><td>IL-10 (pg/mL)</td><td>28.47 &#177; 20.05</td><td>33.02 &#177; 27.87</td><td>0.50</td></tr><tr><td>IP-10 (pg/mL)</td><td>571 &#177; 418</td><td>689 &#177; 617</td><td>0.54</td></tr><tr><td>TNF-&#945; (pg/mL)</td><td>127 &#177; 40</td><td>123 &#177; 31</td><td>0.65</td></tr><tr><td>hsCRP (&#956;g/mL)</td><td>5.38 &#177; 3.91</td><td>6.36 &#177; 4.52</td><td>0.24</td></tr></table>
75f5e8d72ea49b182ae49c18396ce62655bdb9d12549903a150b7e3628797d23.png
complex
<table><tr><td>Working countries</td><td colspan="2">Health problems suffered during last 12 month</td><td>Total</td></tr><tr><td></td><td>Yes (%)</td><td>No (%)</td><td></td></tr><tr><td>Qatar</td><td>120 (58.5)</td><td>85 (41.5)</td><td>205</td></tr><tr><td>Saudi Arabia</td><td>74 (54.0)</td><td>63 (46.0)</td><td>137</td></tr><tr><td>United Arab Emirates</td><td>37 (56.1)</td><td>29 (43.9)</td><td>66</td></tr><tr><td>Total</td><td>231 (56.6)</td><td>177 (43.4)</td><td>408</td></tr><tr><td>Working countries</td><td colspan="2">Accident at the work place</td><td>Total</td></tr><tr><td></td><td>Yes (%)</td><td>No (%)</td><td></td></tr><tr><td>Qatar</td><td>47 (22.9)</td><td>158 (77.1)</td><td>205</td></tr><tr><td>Saudi Arabia</td><td>36 (26.3)</td><td>101 (73.7)</td><td>137</td></tr><tr><td>United Arab Emirates</td><td>19 (28.8)</td><td>47 (71.2)</td><td>66</td></tr><tr><td>Total</td><td>102 (25.0)</td><td>306 (75.0)</td><td>408</td></tr></table>
94be6a95c5841f0550402775c72a7050e59197c5483342696440c783a2b993d3.png
complex
<table><tr><td></td><td colspan="2">Univariate logistic regression</td><td colspan="2">Multivariable logistic regression</td></tr><tr><td>Variable</td><td>OR (95% CI)</td><td>p-value</td><td>OR (95% CI)</td><td>p-value</td></tr><tr><td>Year</td><td></td><td></td><td></td><td></td></tr><tr><td><i>For every 1-year increase</i></td><td>1.11 (1.02 &#8211; 1.20)</td><td>0.01</td><td>1.12 (1.02 &#8211; 1.24)</td><td>0.02</td></tr><tr><td>Site</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Lung</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Breast</i></td><td>1.38 (0.82 &#8211; 2.33)</td><td>0.22</td><td>1.34 (0.70 &#8211; 2.56)</td><td>0.38</td></tr><tr><td><i>Liver/colorectal/stomach</i></td><td>0.66 (0.34 &#8211; 1.27)</td><td>0.21</td><td>0.52 (0.24 &#8211; 1.10)</td><td>0.09</td></tr><tr><td>Funding</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Not for profit/Mixed</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Industry</i></td><td>3.63 (2.00 &#8211; 6.58)</td><td>&lt;.0001</td><td>3.54 (1.85 &#8211; 6.78)</td><td>0.0001</td></tr><tr><td><i>Not specified</i></td><td>0.88 (0.44 &#8211; 1.79)</td><td>0.73</td><td>0.95 (0.45 - 2.03)</td><td>0.90</td></tr><tr><td>Multi-center</td><td></td><td></td><td></td><td></td></tr><tr><td><i>No</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Yes</i></td><td>1.24 (0.77 &#8211; 2.00)</td><td>0.38</td><td>0.91 (0.52 &#8211; 1.58)</td><td>0.74</td></tr><tr><td>Placebo-controlled</td><td></td><td></td><td></td><td></td></tr><tr><td><i>No</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Yes</i></td><td>3.08 (1.57 &#8211; 6.07)</td><td>0.001</td><td>2.57 (1.19 &#8211; 5.54)</td><td>0.02</td></tr><tr><td>Treatment type</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Basic/Limited</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Enhanced/Maximal</i></td><td>1.11 (0.68 &#8211; 1.82)</td><td>0.68</td><td>0.61 (0.32 &#8211; 1.16)</td><td>0.13</td></tr><tr><td>Treatment aim</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Adjuvant</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Both</i></td><td>3.67 (1.48 &#8211; 9.06)</td><td>0.005</td><td>5.12 (1.81 &#8211; 14.48)</td><td>0.002</td></tr><tr><td><i>Metastatic</i></td><td>3.38 (1.75 &#8211; 6.55)</td><td>0.0003</td><td>4.00 (1.90 &#8211; 8.43)</td><td>0.0003</td></tr><tr><td><i>Supportive measures</i></td><td>2.67 (0.91 &#8211; 7.79)</td><td>0.07</td><td>1.21 (0.35 &#8211; 4.17)</td><td>0.76</td></tr><tr><td>Design</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Factorial/multiple arms</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Simple 2 arm</i></td><td>0.96 (0.49 &#8211; 1.90)</td><td>0.91</td><td>0.73 (0.34 &#8211; 1.58)</td><td>0.43</td></tr><tr><td>Ethics</td><td></td><td></td><td></td><td></td></tr><tr><td><i>Not documented</i></td><td>1.00</td><td>Referent</td><td>1.00</td><td>Referent</td></tr><tr><td><i>Documented</i></td><td>1.36 (0.73 &#8211; 2.54)</td><td>0.33</td><td>0.76 (0.37 &#8211; 1.56)</td><td>0.45</td></tr></table>
077c32b755ee7c6a0af9540c6cd4c5a237d935fa3b36e03696a0e63ad37e6705.png
simple
<table><tr><td>Studies</td><td><i>n</i></td><td>Procedures</td><td>Mean age &#177; SD (yr) (min&#8211;max)</td><td>Described complication</td><td>% found in each study</td><td>Equivalent % in our cohort</td></tr><tr><td>Sury et al., 1999 [3]</td><td>1155</td><td>MRI</td><td>N/A</td><td>Failure</td><td>5</td><td>2.3</td></tr><tr><td>Beebe et al., 2000 [9]</td><td>572</td><td>MRI</td><td>5 &#177; 4(2 mo&#8211;14 yo)</td><td>Inadequate sedation</td><td>7.9</td><td>7.3</td></tr><tr><td></td><td></td><td></td><td></td><td>Total</td><td>20.1</td><td>22</td></tr><tr><td>Malviya et al., 1997 [1]</td><td>1140</td><td>MRI (48%) CT (27%) Cardiac (22%)</td><td>3 &#177; 3.7</td><td>Inadequate sedationFailureDesaturation &#8804;90%</td><td>13.23.785.5</td><td>82.35.77</td></tr><tr><td></td><td></td><td></td><td></td><td>Total</td><td>6.52</td><td>22</td></tr><tr><td>Lightdale et al., 2009 [11]</td><td>5045</td><td>Imaging (81%)</td><td>3.3 (1.4&#8211;6.4)</td><td>Serious adverse events*FailureDesaturation<sup>&#167;</sup></td><td>1.921.170.57</td><td>02.30</td></tr><tr><td>Haque and Fadoo, 2010 [12]</td><td>499</td><td>Oncology</td><td>4.2 (6 mo&#8211;14 yo)</td><td>Desaturation<sup>&#165;</sup>Apnea</td><td>2.40.6</td><td>5.770</td></tr><tr><td>Cravero et al., 2006 [13]</td><td>30037</td><td>Imaging (60%) Oncology (9%) GI (6%)</td><td>0&#8211;6 mo : 6% 6 mo&#8211;2 yo : 23% 2&#8211;8 yo : 47% 8 yo+ : 29%</td><td>Desaturation &#8804;90%Apnea</td><td>1.570.24</td><td>5.770</td></tr><tr><td>Cravero et al., 2009 [10]</td><td>49836</td><td>Imaging (60%) Oncology (14%) GI (11%)</td><td>0&#8211;6 mo : 2% 6&#8211;12 mo : 6% 1-2 yo : 12% 2&#8211;4 yo : 21% 4&#8211;8 yo : 28%8 yo+ : 29%</td><td>Desaturation &#8804;90% for 30 sApnea</td><td>1.545.75</td><td>5.770</td></tr><tr><td>Lavoie, 2012</td><td>448</td><td>Imaging (41%) GI (10%)</td><td>4.1 &#177; 4.3 (1 mo&#8211;18 yo)</td><td>FailureDesaturation &#8804;90%ApneaMajor complication</td><td>2.35.7700</td><td>&#8212;&#8212;&#8212;&#8212;</td></tr></table>
34ecc799e700053f7eb9f769cd6ad845b2df36e2cbcb4309a7a71f35c78c6969.png
complex
<table><tr><td>Method</td><td>Temporal resolution</td><td>Measure</td><td>Span of interest</td><td colspan="2">General functionality</td><td>Hypothesized emotion-related functionality</td></tr><tr><td>ERP</td><td>Higher (as low as 1 ms)</td><td>Amplitude fluctuations evoked by stimulus</td><td>Short (&#8764;1 s)</td><td>Early (e.g., P1, N1, N170)</td><td>Perceptual feature extraction</td><td>Early selective attention to affective stimuli</td></tr><tr><td></td><td></td><td></td><td></td><td>Middle (e.g., P2, N2)</td><td>Executive control, selective attention</td><td>Retrieving concept knowledge for evaluation of affective state</td></tr><tr><td></td><td></td><td></td><td></td><td>Late (e.g., P3, N4, Late Positive Potential)</td><td>Semantic processing, memory, evaluation</td><td>Using concept knowledge for evaluation of affective state</td></tr><tr><td>ERD/ERS</td><td>Lower [few multiple of ERPs (Kno&#776;sche and Bastiaansen, 2002)]</td><td>Decrease or increase of induced power in given frequency band</td><td>Long (1 s&#8764;)</td><td>Activation or suppression of cortical activity. Alpha band oscillation is related to the access to concept knowledge. Gamma band is associated with processing of affective stimuli.</td></tr></table>
c3a2341ab7b7e2eeb89cb55bee65aa60a76bc86b043390bc99fc754ca0f1ad73.png
simple
<table><tr><td></td><td>Odds ratio (95% confidence interval)</td><td>P value</td></tr><tr><td>Age</td><td>1.04 (1.01-1.07)</td><td>0.0022</td></tr><tr><td>BMI</td><td>0.98 (0.93-1.03)</td><td>0.4578</td></tr><tr><td>Female sex</td><td>0.79 (0.47-1.34)</td><td>0.3952</td></tr><tr><td>DR</td><td>1.71 (1.03-2.85)</td><td>0.0366</td></tr><tr><td>Hypertension</td><td>1.78 (1.05-3.00)</td><td>0.0300</td></tr><tr><td>Dyslipidaemia</td><td>1.16 (0.71-1.89)</td><td>0.5505</td></tr><tr><td>Smoking</td><td>2.17 (1.13-4.14)</td><td>0.0109</td></tr><tr><td>eGFR</td><td>1.00 (0.99-1.01)</td><td>0.3345</td></tr><tr><td>UAE</td><td>0.99 (0.99-1.00)</td><td>0.6397</td></tr></table>
4ce9deef60240ee5914d52e6a5479745b486753c21666ce3f346437e04e69e2b.png
simple
<table><tr><td></td><td>Cavus</td><td>Neutral</td><td>Planus</td><td>P-value</td></tr><tr><td>N (female)</td><td>53 (5)</td><td>184 (34)</td><td>711 (133)</td><td></td></tr><tr><td>AHF (mm/kN)</td><td>13.2 &#177; 7.4</td><td>14.8 &#177; 7.4</td><td>16.6 &#177; 7.4</td><td>0.0001 <sup>a,c</sup></td></tr><tr><td>&#916;Foot Length (mm)</td><td>4.8 &#177; 2.6</td><td>4.3 &#177; 2.2</td><td>3.6 &#177; 2.1</td><td>&lt;.0001 <sup>a,c</sup></td></tr></table>
59e81cbef37f8ac237f95278ac56a194e3f56361fe6261540d281df1569731db.png
complex
<table><tr><td rowspan="2">Climate model</td><td colspan="3">Seasonal mean temperature (<sup>o</sup>C)</td><td colspan="3">Seasonal cumulated rainfall (mm)</td></tr><tr><td>2030</td><td>2050</td><td>2070</td><td>2030</td><td>2050</td><td>2070</td></tr><tr><td><i>ACCESS1-0</i></td><td>14.3 &#177; 1.7</td><td>15.1 &#177; 1.8</td><td>16.1 &#177; 1.9</td><td>230.8 &#177; 89.9</td><td>213.2 &#177; 88.8</td><td>207.6 &#177; 84.1</td></tr><tr><td><i>ACCESS1-3</i></td><td>14.5 &#177; 1.8</td><td>15.4 &#177; 1.9</td><td>16.5 &#177; 2.0</td><td>220.4 &#177; 88.9</td><td>185.4 &#177; 74.6</td><td>151.0 &#177; 62.9</td></tr><tr><td><i>bcc-csm1-1</i></td><td>14.2 &#177; 1.7</td><td>14.8 &#177; 1.8</td><td>15.8 &#177; 1.8</td><td>222.6 &#177; 85.8</td><td>219.2 &#177; 84.7</td><td>193.0 &#177; 80.1</td></tr><tr><td><i>bcc-csm1-1-m</i></td><td>14.8 &#177; 1.8</td><td>15.3 &#177; 1.8</td><td>16.1 &#177; 1.8</td><td>224.3 &#177; 91.3</td><td>217.0 &#177; 83.7</td><td>210.6 &#177; 83.9</td></tr><tr><td><i>BNU-ESM</i></td><td>14.3 &#177; 1.8</td><td>15.2 &#177; 1.8</td><td>16.7 &#177; 1.8</td><td>262.5 &#177; 102.3</td><td>233.4 &#177; 91.1</td><td>175.3 &#177; 67.9</td></tr><tr><td><i>CanESM2</i></td><td>14.5 &#177; 1.9</td><td>15.4 &#177; 2.0</td><td>16.7 &#177; 2.0</td><td>210.3 &#177; 82.4</td><td>203.9 &#177; 81.2</td><td>190.6 &#177; 74.8</td></tr><tr><td><i>CCSM4</i></td><td>14.3 &#177; 1.8</td><td>15.1 &#177; 1.7</td><td>16.1 &#177; 1.7</td><td>230.9 &#177; 89.9</td><td>238.0 &#177; 93.8</td><td>230.4 &#177; 92.3</td></tr><tr><td><i>CESM1-BGC</i></td><td>14.4 &#177; 1.8</td><td>15.0 &#177; 1.8</td><td>16.1 &#177; 1.8</td><td>245.2 &#177; 96.0</td><td>247.7 &#177; 94.6</td><td>224.3 &#177; 87.7</td></tr><tr><td><i>CESM1-CAM5</i></td><td>14.4 &#177; 1.8</td><td>15.1 &#177; 1.8</td><td>16.5 &#177; 1.9</td><td>235.5 &#177; 92.1</td><td>219.0 &#177; 87.4</td><td>208.2 &#177; 82.0</td></tr><tr><td><i>CESM1-WACCM</i></td><td>14.3 &#177; 1.7</td><td>15.1 &#177; 1.7</td><td>15.8 &#177; 1.7</td><td>231.4 &#177; 90.6</td><td>227.9 &#177; 89.6</td><td>229.5 &#177; 90.8</td></tr><tr><td><i>CNRM-CM5</i></td><td>14.0 &#177; 1.7</td><td>14.8 &#177; 1.8</td><td>15.5 &#177; 1.8</td><td>220.1 &#177; 87.6</td><td>215.6 &#177; 87.5</td><td>216.8 &#177; 85.6</td></tr><tr><td><i>CSIRO-Mk3-6-0</i></td><td>14.1 &#177; 1.8</td><td>14.9 &#177; 1.9</td><td>15.9 &#177; 2.0</td><td>198.9 &#177; 80.6</td><td>181.5 &#177; 74.4</td><td>150.7 &#177; 64.8</td></tr><tr><td><i>FGOALS-g2</i></td><td>14.1 &#177; 1.8</td><td>14.6 &#177; 1.9</td><td>15.0 &#177; 1.8</td><td>212.2 &#177; 84.5</td><td>212.5 &#177; 86.5</td><td>254.5 &#177; 107.2</td></tr><tr><td><i>FIO-ESM</i></td><td>14.2 &#177; 1.7</td><td>15.0 &#177; 1.7</td><td>16.2 &#177; 1.7</td><td>232.6 &#177; 90.9</td><td>235.7 &#177; 92.1</td><td>219.7 &#177; 86.1</td></tr><tr><td><i>GFDL-CM3</i></td><td>14.1 &#177; 1.9</td><td>14.9 &#177; 2.0</td><td>16.2 &#177; 2.2</td><td>213.1 &#177; 83.5</td><td>190.6 &#177; 78.3</td><td>153.8 &#177; 66.3</td></tr><tr><td><i>GFDL-ESM2G</i></td><td>14.0 &#177; 1.8</td><td>14.7 &#177; 1.9</td><td>15.4 &#177; 1.9</td><td>215.0 &#177; 88.5</td><td>197.5 &#177; 82.4</td><td>186.9 &#177; 80.4</td></tr><tr><td><i>GFDL-ESM2M</i></td><td>14.3 &#177; 1.9</td><td>14.8 &#177; 2.0</td><td>15.7 &#177; 2.1</td><td>188.1 &#177; 76.2</td><td>165.7 &#177; 70.0</td><td>147.4 &#177; 62.9</td></tr><tr><td><i>GISS-E2-H</i></td><td>14.0 &#177; 1.8</td><td>15.0 &#177; 1.7</td><td>15.9 &#177; 1.8</td><td>229.8 &#177; 89.0</td><td>225.5 &#177; 89.3</td><td>212.8 &#177; 86.3</td></tr><tr><td><i>GISS-E2-H-CC</i></td><td>14.0 &#177; 1.7</td><td>14.8 &#177; 1.7</td><td>15.5 &#177; 1.7</td><td>233.2 &#177; 93.2</td><td>223.0 &#177; 91.9</td><td>227.4 &#177; 92.5</td></tr><tr><td><i>GISS-E2-R</i></td><td>14.1 &#177; 1.7</td><td>14.8 &#177; 1.8</td><td>15.5 &#177; 1.8</td><td>252.6 &#177; 97.7</td><td>239.6 &#177; 93.8</td><td>242.7 &#177; 95.6</td></tr><tr><td><i>GISS-E2-R-CC</i></td><td>14.2 &#177; 1.8</td><td>15.0 &#177; 1.8</td><td>15.9 &#177; 1.8</td><td>228.4 &#177; 89.1</td><td>221.2 &#177; 87.5</td><td>214.7 &#177; 84.4</td></tr><tr><td><i>HadGEM2-AO</i></td><td>14.1 &#177; 1.8</td><td>14.9 &#177; 1.8</td><td>16.0 &#177; 1.9</td><td>230.8 &#177; 91.3</td><td>216.0 &#177; 87.2</td><td>200.2 &#177; 79.1</td></tr><tr><td><i>HadGEM2-CC</i></td><td>14.5 &#177; 1.7</td><td>15.3 &#177; 1.8</td><td>16.1 &#177; 1.9</td><td>219.5 &#177; 86.9</td><td>210.8 &#177; 83.3</td><td>199.3 &#177; 80.5</td></tr><tr><td><i>HadGEM2-ES</i></td><td>14.5 &#177; 1.7</td><td>15.4 &#177; 1.8</td><td>16.4 &#177; 1.9</td><td>231.9 &#177; 91.3</td><td>204.6 &#177; 80.0</td><td>177.7 &#177; 71.3</td></tr><tr><td><i>inmcm4</i></td><td>13.9 &#177; 1.8</td><td>14.5 &#177; 1.8</td><td>15.2 &#177; 1.9</td><td>246.7 &#177; 97.3</td><td>240.0 &#177; 94.9</td><td>220.0 &#177; 86.2</td></tr><tr><td><i>IPSL-CM5A-LR</i></td><td>14.5 &#177; 1.8</td><td>15.4 &#177; 1.9</td><td>16.6 &#177; 1.9</td><td>208.7 &#177; 86.4</td><td>199.9 &#177; 83.1</td><td>180.9 &#177; 74.6</td></tr><tr><td><i>IPSL-CM5A-MR</i></td><td>14.5 &#177; 1.8</td><td>15.4 &#177; 1.9</td><td>16.9 &#177; 1.9</td><td>198.5 &#177; 79.2</td><td>192.1 &#177; 76.9</td><td>159.4 &#177; 66.1</td></tr><tr><td><i>IPSL-CM5B-LR</i></td><td>14.1 &#177; 1.8</td><td>14.8 &#177; 1.9</td><td>15.8 &#177; 1.9</td><td>224.0 &#177; 87.7</td><td>210.2 &#177; 81.9</td><td>201.2 &#177; 79.2</td></tr><tr><td><i>MIROC5</i></td><td>14.1 &#177; 1.8</td><td>14.7 &#177; 1.8</td><td>15.4 &#177; 1.9</td><td>234.0 &#177; 90.5</td><td>221.4 &#177; 86.2</td><td>230.9 &#177; 90.7</td></tr><tr><td><i>MIROC-ESM</i></td><td>14.1 &#177; 1.6</td><td>14.8 &#177; 1.6</td><td>15.8 &#177; 1.7</td><td>242.2 &#177; 96.4</td><td>251.1 &#177; 103.2</td><td>229.3 &#177; 100.3</td></tr><tr><td><i>MIROC-ESM-CHEM</i></td><td>14.1 &#177; 1.6</td><td>14.8 &#177; 1.6</td><td>15.8 &#177; 1.6</td><td>249.6 &#177; 100.3</td><td>251.3 &#177; 102.5</td><td>229.2 &#177; 97.5</td></tr><tr><td><i>MRI-CGCM3</i></td><td>13.9 &#177; 1.7</td><td>14.6 &#177; 1.6</td><td>15.3 &#177; 1.7</td><td>227.5 &#177; 88.9</td><td>224.3 &#177; 93.4</td><td>220.1 &#177; 93.1</td></tr><tr><td><i>NorESM1-M</i></td><td>14.0 &#177; 1.7</td><td>14.8 &#177; 1.7</td><td>15.5 &#177; 1.7</td><td>230.1 &#177; 91.5</td><td>221.3 &#177; 91.3</td><td>233.9 &#177; 103.2</td></tr></table>
efb3836579f5a42ae21da830136f2589cdc91385e84e03014929167311a79fba.png
complex
<table><tr><td></td><td colspan="2">Changes in WHtR*<sup>1&#182;</sup></td><td colspan="2">Changes in weight*<sup>2</sup> [kg]</td><td colspan="2">Changes in BMI percentiles*<sup>3</sup></td></tr><tr><td></td><td>(<i>n</i> = 1252)</td><td></td><td>(<i>n</i> = 1251)</td><td></td><td>(<i>n</i> = 1250)</td><td></td></tr><tr><td></td><td><i>B</i> (SE)</td><td><i>p</i>-value</td><td><i>B</i> (SE)</td><td><i>p</i>-value</td><td><i>B</i> (SE)</td><td><i>p</i>-value</td></tr><tr><td>Skipping breakfast</td><td><i>0.50 (0.19)</i></td><td><i>0.007**</i></td><td><i>0.39 (0.12)</i></td><td><i>&lt;0.001***</i></td><td><i>2.01 (0.90)</i></td><td><i>0.027*</i></td></tr><tr><td>Soft drinks &gt; 1 time per week</td><td>-0.01 (0.15)</td><td>0.966</td><td>-0.08 (0.09)</td><td>0.385</td><td>-0.75 (0.70)</td><td>0.282</td></tr><tr><td>Screen media &gt; 1 h/day</td><td>0.29 (0.16)</td><td>0.074</td><td>0.19 (0.10)</td><td>0.054</td><td>0.70 (0.78)</td><td>0.373</td></tr></table>